ITEM 1. BUSINESS 	 -------- GENERAL
Forest Laboratories, Inc. and its subsidiaries (collectively, "Forest" or the "Company") develop, manufacture and sell both branded and generic forms of ethical drug products which require a physician's prescription, as well as non-prescription pharmaceutical products sold over-the-counter. Forest's most important United States products consist of branded ethical drug specialties marketed directly, or "detailed," to physicians by the Company's salesforce and its controlled release line of generic products sold to wholesalers, chain drug stores and generic distributors. In recent years the Company has emphasized increased detailing to physicians of those branded ethical drugs it believes have the most potential for growth, and the introduction of new products acquired from other companies or developed by the Company.
Forest's products include those developed by Forest and those acquired from other pharmaceutical companies and integrated into Forest's marketing and distribution systems. See "Recent Developments."
Forest is a Delaware corporation organized in 1956, and its principal executive offices are located at 150 East 58th Street, New York, New York 10155-10015 (telephone number (212-421-7850).
RECENT DEVELOPMENTS
PROSTAGLANDIN E(2) INSERT: In October 1993, Forest entered into a license and supply agreement granting Forest exclusive United States rights to develop and market a pessary infused with the hormone Prostaglandin E(2). The product will be used for the initiation or continuation of cervical ripening in patients where there is a medical or obstetrical indication for the induction of labor. A New Drug Application (an "NDA") was filed with the United States Food and Drug Administration (the "FDA") with respect to this product in December 1993. The Company plans to market this product under the brand name Cervidil-TM- C.R.
FLUMADINE: In September 1993, Forest received the approval of the FDA to market rimantadine, an antiviral agent used for the treatment and prophylaxis of Influenza A. The Company markets this product under the trademark Flumadine-R-.
FOSFOMYCIN TROMETAMOL: In November 1991, the Company entered into a licensing agreement with the Zambon Group of Italy for the marketing by the Company in the United States of the antibiotic fosfomycin trometamol. Fosfomycin trometamol is currently approved for marketing in eleven countries, including the United Kingdom, Germany, Italy and Spain, under the brand name Monurol-R-. The product is a single dose antibiotic used for the treatment of uncomplicated urinary tract infections. There are currently no single dose antibiotics approved for this indication in the United States. It is currently anticipated that an NDA will be filed for the product in 1994.
INFASURF: In June 1991, the Company entered into a licensing agreement with ONY, Inc. for the marketing by the Company in the United States, the United Kingdom and Canada of the product Infasurf-R- for the treatment of respiratory distress syndrome in premature infants. Such licensing arrangements were expanded in May 1992 to include worldwide rights to the product. Infasurf is currently in Phase III clinical trials in the United States. The Company is also conducting early stage clinical trials of Infasurf in order to evaluate its possible use in adult respiratory distress syndrome. It is currently anticipated that an NDA will be filed for the product in 1994.
SYNAPTON: The Company is conducting multi-center clinical trials to study the safety and efficacy of Synapton-TM- for the treatment of Alzheimer's Disease. Synapton contains physostigmine, a cholinesterase inhibitor. Cholinesterase is an enzyme which metabolizes or breaks down acetylcholine, which is the neurotransmitter in the brain most associated with memory. It is believed that in Alzheimer's patients, the cells that produce acetylcholine progressively die, and it is the reduced availability of this important neurotransmitter that is believed to contribute to the patient's mental deterioration. Synapton is formulated to partially inhibit cholinesterase activity so that the acetylcholine produced by the body is available for a longer period of time. It is recognized that cholinesterase inhibitors generally are not a cure for Alzheimer's Disease but are expected to have an ameliorative effect for certain patients.
Synapton is a controlled release formulation of physostigmine. Synapton makes use of Forest's patented Synchron-R- technology which provides for the continuous release of medication into the bloodstream and, in the case of Synapton, permits twice-a-day administration. The Company has concluded one Phase III clinical study which demonstrates Synapton's effectiveness. The Company hopes to complete a second successful Phase III study which would enable an NDA to be filed.
MICTURIN: In August 1989, Forest completed and submitted a full NDA to the FDA covering Micturin-R-, which is
licensed to Forest in the United States by the Swedish pharmaceutical manufacturer Pharmacia AB ("Pharmacia"). The product had been marketed outside the United States by Pharmacia since 1986 and by 1991 was approved and marketed in 20 countries, with over 400 million doses having been sold. In mid-1991, some cases of a rare but serious cardiac side effect, polymorphic ventricular tachycardia, were reported principally in the United Kingdom among patients taking Micturin. In all but a few of those cases, the patients appeared to have identifiable predisposing risk factors. As a result of those reports, the United Kingdom Committee on the Safety of Medicines (the "CSM") sent a letter to physicians and pharmacists advising them of those reported cases and contraindicating the drug for patients with the predisposing risk factors. In September 1991, following the CSM action and after regulatory action in other markets, including withdrawals of the product in Germany and Austria, Pharmacia withdrew Micturin from all markets worldwide. Following the worldwide withdrawal of Micturin, the FDA requested that Forest discontinue its ongoing studies of Micturin in the United States until the FDA could review the possible relationship between the use of Micturin and the reported cardiac side effect. Forest is presently conducting clinical studies to further assess Micturin's safety.
PRINCIPAL PRODUCTS
The Company actively promotes in the United States those of its branded products which the Company's management believes have the most potential for growth and which enable its salesforce to concentrate on specialty groups of physicians who are high prescribers of its products. Such products include the respiratory products Aerobid-R-, Aerochamber-R- and Tessalon-R-, the thyroid product Levothroid-R-, the ESGIC-R- and Lorcet-R- lines of analgesics and Flumadine (See "Recent Developments").
Aerobid is a metered dose inhaled steroid used in the treatment of asthma. Sales of Aerobid accounted for 21.3% of Forest's sales for the fiscal year ended March 31, 1994 as compared to 17.7% and 14.2% for the fiscal years ended March 31, 1993 and 1992, respectively. During fiscal 1992, the National Institutes of Health recommended inhaled steroid therapy as a first-line therapy for an expanded group of asthma patients, rather than bronchodilators (such as beta-2-agonists and theophylline). This recommendation has resulted in the increased use of metered dose inhaled corticosteroids such as Aerobid. Aerochamber is a spacer device used to improve the delivery of aerosol administered products, including Aerobid.
ESGIC and its line extension, ESGIC Plus, are combination analgesic/sedatives for the relief of tension headaches, while Lorcet is a line of potent analgesics. Lorcet
sales accounted for 11.2% of sales for the fiscal year ended March 31, 1994, as compared to 7.8% and 6.7% of sales for the fiscal years ended March 31, 1993 and 1992, respectively. Tessalon is a solid dose non-narcotic cough suppressant. Sales of Tessalon (including sales of a generic formulation) accounted for 6.0% of sales for the fiscal year ended March 31, 1994, as compared to 10.9% and 7.9% for the fiscal years ended March 31, 1993 and 1992, respectively.
Forest's generic line emphasizes the Company's capability to produce difficult to formulate controlled release products which are sold in the United States by Forest's Inwood Laboratories, Inc. subsidiary. Inwood's most important products include Propranolol E.R., a controlled release beta blocker used in the treatment of hypertension, Indomethacin E.R., a controlled release non-steroidal anti-inflammatory drug used in the treatment of arthritis, and Theochron-TM- , a controlled release theophylline tablet used in treatment of asthma. Sales of Propranolol accounted for 14.3% of Forest's sales for the fiscal year ended March 31, 1994, as compared to 14.1% and 12.5% for the fiscal years ended March 31, 1993 and 1992, respectively.
The Company's United Kingdom and Ireland subsidiaries sell both ethical products requiring a doctor's prescription and over-the-counter preparations. Their most important products include Sudocrem, a topical preparation for the treatment of diaper rash, Colomycin, an antibiotic used in the treatment of Cystic Fibrosis and Suscard and Sustac, sustained action nitroglycerin tablets in both buccal and oral form used in the treatment of angina pectoris, an ailment characterized by insufficient oxygenation of the heart muscle.
MARKETING
In the United States, Forest directly markets its products through its domestic salesforce, currently numbering 450 persons, which details products directly to physicians, pharmacies and managed care organizations. The expansion of Forest's direct sales efforts and related promotional activities has significantly increased sales of Forest's branded ethical pharmaceutical products, including certain of those acquired or licensed by Forest. See "Principal Products". In the United Kingdom, the Company's Pharmax subsidiary's salesforce, currently 62 persons, markets its products directly. Forest's products are sold elsewhere through independent distributors.
COMPETITION
The pharmaceutical industry is highly competitive as to the sale of products, research for new or improved products and the development and application of competitive controlled release technologies. There are numerous companies in the United States and abroad engaged in the manufacture and sale of both proprietary and generic drugs of the kind sold by Forest and drugs utilizing controlled release technologies. Many of these companies have substantially greater financial resources than Forest. In addition, the marketing of pharmaceutical products is increasingly affected by the growing role of managed care organizations in the provision of health services. Such organizations negotiate with pharmaceutical manufacturers for highly competitive prices for pharmaceutial products in equivalent therapeutic categories, including certain of the Company's principal promoted products.
GOVERNMENT REGULATION
The pharmaceutical industry is subject to comprehensive government regulation which substantially increases the difficulty and cost incurred in obtaining the approval to market newly proposed drug products and maintaining the approval to market existing drugs. In the United States, products developed, manufactured or sold by Forest are subject to regulation by the FDA, principally under the Federal Food, Drug and Cosmetic Act, as well as by other federal and state agencies. The FDA regulates all aspects of the testing, manufacture, safety, labeling, storage, record keeping, advertising and promotion of new and old drugs, including the monitoring of compliance with good manufacturing practice regulations. Non-compliance with applicable requirements can result in fines and other sanctions, including the initiation of product seizures, injunction actions and criminal prosecutions based on practices that violate statutory requirements. In addition, administrative remedies can involve voluntary recall of products as well as the withdrawal of approval of products in accordance with due process procedures. Similar regulations exist in most foreign countries in which Forest's products are manufactured or sold. In many foreign countries, such as the United Kingdom, reimbursement under national health insurance programs frequently require that manufacturers and sellers of pharmaceutical products obtain governmental approval of initial prices and increases if the ultimate consumer is to be eligible for reimbursement for the cost of such products.
During the past several years the FDA, in accordance with its standard practice, has conducted a number of inspections of the Company's manufacturing facilities. Following these inspections the FDA called the Company's attention to certain
"Good Manufacturing Practices" compliance and record keeping deficiencies, including a warning letter issued April 22, 1994 with respect to Forest's manufacture of Indomethacin. The Company believes it has satisfactorily remedied these deficiencies.
The cost of human health care products continues to be a subject of investigation and action by governmental agencies, legislative bodies, and private organizations in the United States and other countries and is the focus of legislative efforts by the Clinton Administration in Washington. In the United States, most states have enacted generic substitution legislation requiring or permitting a dispensing pharmacist to substitute a different manufacturer's version of a drug for the one prescribed. Federal and state governments continue to press efforts to reduce costs of Medicare and Medicaid programs, including restrictions on amounts agencies will reimburse for the use of products. Under the Omnibus Budget Reconciliation Act of 1990 (OBRA), manufacturers must pay certain statutorily-prescribed rebates on Medicaid purchases for reimbursement on prescription drugs under state Medicaid plans. Federal Medicaid reimbursement for drug products of original NDA-holders is denied if less expensive generic versions are available from other manufacturers. In addition, the Federal government follows a diagnosis related group (DRG) payment system for certain institutional services provided under Medicare or Medicaid. The DRG system entitles a health care facility to a fixed reimbursement based on discharge diagnoses rather than actual costs incurred in patient treatment, thereby increasing the incentive for the facility to limit or control expenditures for many health care products.
Under the Prescription Drug User Fee Act of 1992, the FDA has imposed fees on various aspects of the approval, manufacture and sale of prescription drugs. The Health Security Act (the "HSA") proposed by the Clinton Administration and currently pending before Congress is highly regulatory and contains provisions which would affect the marketing of prescription drug products. Among other things, the HSA provides for the establishment of an Advisory Council to make recommendations to the Secretary of Health and Human Services as to the reasonableness of new drug prices and contemplates the increased use of managed care programs for the provision of health care services. The debate as to reform of the health care system is expected to be protracted and the Company cannot predict the outcome or effect on the marketing of prescription drug products of the legislative process.
PRINCIPAL CUSTOMERS
No customer accounted for more than 10% of Forest's consolidated sales in the fiscal years ended March 31, 1994 and March 31, 1993.
ENVIRONMENTAL STANDARDS
Forest anticipates that the effects of compliance with federal, state and local laws and regulations relating to the discharge of materials into the environment will not have any material effect on capital expenditures, earnings or the competitive position of Forest.
RAW MATERIALS
The principal raw materials used by Forest for its various products are purchased in the open market. Most of these materials are obtainable and available from several sources in the United States and elsewhere in the world, although certain of Forest's products contain patented or other exclusively manufactured materials available from only a single source. Forest has not experienced any significant shortages in supplies of such raw materials.
PRODUCT LIABILITY INSURANCE
Forest currently maintains $50 million of product liability coverage per "occurrence" and in the aggregate. Although in the past there have been claims asserted against Forest, none for which Forest has been found liable, there can be no assurance that all potential claims which may be asserted against Forest in the future would be covered by Forest's present insurance.
RESEARCH AND DEVELOPMENT
During the year ended March 31, 1994, Forest spent approximately $27,998,000 for research and development, as compared to approximately $22,054,000 and $17,771,000 in the fiscal years ended March 31, 1993 and 1992, respectively. A portion of such funds spent for research and development in the fiscal years ended March 31, 1993 and 1992 was reimbursed to Forest pursuant to research and development contracts with other pharmaceutical companies and pursuant to two research and development agreements with Prutech Research and Development Partnership. Forest's research and development activities during the past year consisted primarily of the conduct of clinical studies required to obtain approval of new products and the development of additional products some of which utilize the Company's controlled release technologies.
EMPLOYEES
At March 31, 1994, Forest had a total of 1,259 employees.
PATENTS AND TRADEMARKS
Forest owns and licenses certain U.S. patents, and has pending U.S. and foreign patent applications, relating to various aspects of its Synchron technology and to other controlled release technology. The patents expire through 2008. Forest believes that patents are useful in its business; however, there are numerous patents and unpatented technologies owned by others covering other controlled release processes.
Forest owns various trademarks and trade names which it believes are of significant benefit to its business.
BACKLOG -- SEASONALITY
Backlog of orders is not considered material to Forest's business prospects. Forest's business is not seasonal in nature.
ITEM 2.
ITEM 2. PROPERTIES 	 ---------- Forest owns six buildings and leases three buildings in and around Inwood, Long Island, New York, containing a total of approximately 140,000 square feet. The buildings are used for manufacturing, research and development, warehousing and administration. Forest has recently acquired a 150,000 square foot building on 28 acres in Commack, New York. The building and land will initially be used for packaging, warehousing and administration and, in the future, for the expansion of Forest's Long Island facilities.
FPI owns two facilities in Cincinnati, Ohio aggregating approximately 140,000 square feet, including a recently acquired facility of 108,000 square feet. In St. Louis, Missouri, FPI owns facilities of 22,000 square feet and 87,000 square feet and leases a 12,000 square foot facility. These facilities are used for manufacturing, warehousing and administration. It is not anticipated that the lease for the 12,000 square foot facility will be renewed. In addition, the Company sold a facility of approximately 35,000 square feet in St. Louis during 1994.
Pharmax owns an approximately 95,000 square foot complex in the London suburb of Bexley, England, which houses its plant and administrative and central marketing offices. Approximately 15,000 square feet of such space is leased by Pharmax to other tenants.
Forest leases two buildings of 39,250 and 34,400 square feet located in Rio Piedras, Puerto Rico, under leases which expire in 1998 subject to one five-year renewal option. The space is used by Sein-Mendez, Forest Laboratories Caribe, Inc. and Forest Pharmaceuticals, Inc., wholly-owned subsidiaries of Forest, for manufacturing, warehousing and administration.
Forest's Tosara subsidiary owns an 18,000 square foot manufacturing and distribution facility located in an industrial park in Dublin, Ireland. A newly-formed subsidiary of Forest has recently commenced the development, together with the Development Authority of the Republic of Ireland of an approximately 86,000 square foot manufacturing and distribution facility to be located in Dublin, Ireland. The facility, expected to be completed in mid-1994, will be used principally for the manufacture and distribution of products in Europe.
Forest's UAD division owns an 18,000 square foot office and distribution facility located in Jackson, Mississippi.
Forest presently leases approximately 37,000 square feet of office space at 150 East 58th Street, New York, New York, subject to a lease which expires in 1995. Forest has recently entered into a lease for a new principal executive office at 909 Third Avenue, New York, New York. The lease covers approximately 70,000 square feet and is for a sixteen (16) year term, subject to 2 five year renewal options.
	 Management believes that the above-described properties, including those under development, are sufficient for Forest's present and anticipated needs.
Net rentals for leased space for the fiscal year ended March 31, 1994 aggregated approximately $1,821,000 and for the fiscal year ended March 31, 1993 aggregated approximately $1,691,000.
ITEM 3.
ITEM 3. LEGAL PROCEEDINGS 	 ----------------- The Company and certain of its officers are currently defendants in WILSON, ET AL. V. FOREST LABORATORIES, INC., ET AL., 91 Civ. 5815 (S.D.N.Y.) (the "Federal Action"), a putative class action that seeks to assert claims based on alleged violations of the Securities Exchange Act of 1934 and common law negligent misrepresentation arising out of certain statements allegedly made by the defendants concerning Micturin.
The Company is the nominal defendant in WEISBERG ET ANO V. CANDEE, ET AL., (Sup. Ct. New York Cty.), a putative derivative action against the directors of the Company seeking to
void certain options granted to the director defendants and require the director defendants to indemnify the Company for any liability resulting from statements concerning Micturin.
The Company believes the claims in both cases are without merit and intends to vigorously defend the actions.
The Company is a defendant in several actions filed in various federal district courts alleging certain violations of the Federal anti-trust laws in the marketing of pharmaceutical products. In each case, the actions were filed against many pharmaceutical manufacturers and suppliers and allege price discrimination and conspiracy to fix prices in the sale of pharmaceutical products. The actions were brought by various pharmacies (certain of which purport to represent a class) and seek injunctive relief and monetary damages. The Judicial Panel on Multi-District Litigation has ordered these actions coordinated (and, with respect to those actions purporting to be class actions, consolidated) in the Federal District Court for the Northern District of Illinois (Chicago) under the caption "In re Brand Name Prescription Drugs Antitrust Litigation." Similar actions alleging price discrimination claims under state law are pending against many pharmaceutical manufacturers, including the Company, in state courts in California and Alabama. The Company believes these actions are without merit and intends to defend them vigorously.
	 The Company is not subject to any other material pending legal proceedings, other than ordinary routine claims incidental to its business.
ITEM 4.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE 	 OF SECURITY HOLDERS 	 ------------------------------- 	 Not Applicable.
PAGE
PART II
ITEM 5.
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS ------------------------------ The information required by this item is incorporated by reference to page 24 of the Annual Report.
	 Forest has never paid cash dividends on its Common Stock and does not expect to pay such dividends in the foreseeable future. Management presently intends to retain all available funds for the development of its business and for use as working capital. Future dividend policy will depend upon Forest's earnings, capital requirements, financial condition and other relevant factors.
ITEM 6.
ITEM 6. SELECTED FINANCIAL DATA 	 ----------------------- The information required by this item is incorporated by reference to page 11 of the Annual Report.
ITEM 7.
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION 	 AND RESULTS OF OPERATIONS 	 ------------------------------- 	 The information required by this item is incorporated by reference to pages 9 and 10 of the Annual Report.
ITEM 8.
ITEM 8. FINANCIAL STATEMENTS AND 	 SUPPLEMENTARY DATA 	 ------------------------ 	 The information required by this item is incorporated by reference to pages 12 through 24 of the Annual Report.
ITEM 9.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING 	 AND FINANCIAL DISCLOSURE ------------------------------ Not Applicable.
PAGE
PART III
	 In accordance with General Instruction G(3), the information called for by Part III (Items 10 through 13) is incorporated by reference from Forest's definitive proxy statement to be filed pursuant to Regulation 14A promulgated under the Securities Exchange Act of 1934 in connection with Forest's 1994 Annual Meeting of Stockholders.
PAGE
PART IV
ITEM 14.
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES 	 AND REPORTS ON FORM 8-K 	 ---------------------------------------
	 (a) 1. Financial statements. The following consolidated 		 financial statements of Forest Laboratories, Inc. 		 and subsidiaries included in the Annual Report 		 are incorporated by reference herein in Item 8:
	 	 Report of Independent Certified Public 	 	 Accountants
	 	 Consolidated balance sheets - 	 March 31, 1994 and 1993
		 Consolidated statements of income - 	 	 years ended March 31, 1994, 1993 and 1992
	 Consolidated statements of shareholders' 		 equity - 	 	 years ended March 31, 1994, 1993 and 1992
		 Consolidated statements of cash flows - 	 	 years ended March 31, 1994, 1993 and 1992
	 	 Notes to consolidated financial statements
	 2. Financial statement schedules. The following 	 	 consolidated financial statement schedules of 		 Forest Laboratories, Inc. and Subsidiaries are 	 	 included herein:
Report of Independent Certified Public Accountants S-1
Schedule II Amounts receivable from related 	 parties and underwriters, promoters 	 and employees other than related 	 parties S-2
Schedule VIII Valuation and qualifying accounts S-3
Schedule X Supplementary income statement 	 information S-4
All other schedules for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission are not required under the related instructions or are inapplicable, and therefore have been omitted. 			
	 3. Exhibits:
(3)(a) Articles of Incorporation of Forest, as amended. 	 Incorporated by reference from the Current Report 	 on Form 8-K dated March 9, 1981 filed by Forest, 	 from Registration Statement on Form S-1 	 (Registration No. 2-97792) filed by Forest on May 	 16, 1985, from Forest's definitive proxy statement 	 filed pursuant to Regulation 14A with respect to 	 Forest's 1987, 1988 and 1993 Annual Meetings of 	 Shareholders and from the Current Report on Form 	 8-K dated March 15, 1988.
(3)(b) By-laws of Forest. Incorporated by reference from 	 Form 10-K for the fiscal year ended March 31, 1981 	 filed by Forest on June 26, 1981.
(10) Material Contracts 	 ------------------ 	 10.1 Option Agreement and Registration Rights 			 Agreement dated February 18, 1988 between 			 Forest and Howard Solomon. Incorporated 	 by reference to Forest's Annual Report on 	 Form 10-K for the fiscal year ended March 	 	 31, 1988 (the "1988 10-K").
	 10.2 Option Agreement and Registration Rights Agreement dated February 18, 1988 between Forest and Joseph M. Schor. Incorporated by reference to the 1988 10-K.
10.3 Option Agreement and Registration Rights Agreement dated February 18, 1988 between Forest and Kenneth E. Goodman. Incorporated by reference to the 1988 		 10-K.
10.4 Option Agreement and Registration Rights 		 Agreement dated February 18, 1988 between Forest and Phillip M. Satow. Incorporated by reference to the 1988 10-K.
10.5 Benefit Continuation Agreement dated as 		 of December 1, 1989 between Forest and Howard Solomon. Incorporated by reference to Forest's Annual Report on Form 10-K for the fiscal year ended March 31, 1990 (the "1990 l0-K").
10.6 Benefit Continuation Agreement dated as 	 		 of December 1, 1989 between Forest and Joseph M. Schor. Incorporated by reference to the 1990 10-K.
10.7 Benefit Continuation Agreement dated as 	 of May 27, 1990 between Forest and Kenneth E. Goodman. Incorporated by reference to the 1990 10-K.
10.8 Benefit Continuation Agreement dated as of December 10, 1989 between Forest and 		 Phillip M. Satow. Incorporated by reference to the 1990 10-K.
10.9 Option Agreement dated December 10, 1990 	 between Forest and Howard Solomon. Incorporated by reference to Forest's Annual Report on Form 10-K for the fiscal year ended March 31, 1991 (the "1991 10-K").
10.10 Option Agreement dated December 10, 1990 		 between Forest and Joseph M. Schor. Incorporated by reference to the 1991 10-K.
10.11 Option Agreement dated December 10, 1990 	 between Forest and Kenneth E. Goodman. Incorporated by reference to the 1991 10-K.
10.12 Option Agreement dated December 10, 1990 between Forest and Phillip M. 			 Satow. Incorporated by reference to the 1991 10-K.
10.13 Split Dollar Life Insurance Agreement dated March 29, 1994 between Forest and Howard Solomon.
10.14 Split Dollar Life Insurance Agreement dated March 29, 1994 between Forest and 	 Joseph M. Schor.
10.15 Split Dollar Life Insurance Agreement 	 dated March 29, 1994 between Forest and Phillip M. Satow.
10.16 Split Dollar Life Insurance Agreement dated March 29, 1994 between Forest and Kenneth E. Goodman.
(13) Portions of the Registrant's Annual 	 	 Report to Stockholders.
	 	22 List of Subsidiaries. Incorporated by 		 reference to Exhibit 22 to the 1988 	 		 10-K.
		24 (a) Consent of BDO Seidman
PAGE
SIGNATURES
	Pursuant to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, Forest has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: June 24, 1994 	 			 FOREST LABORATORIES, INC.
	 			 By: /s/ Howard Solomon 				 -------------------------- 					 Howard Solomon, 				 President, Chief Executive 		 			 Officer and Director
	 Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of Forest and in the capacities and on the dates indicated.
PRINCIPAL EXECUTIVE OFFICER:
/s/ Howard Solomon President, Chief June 24, 1994 - - --------------------------- Executive Officer Howard Solomon and Director
PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER:
/s/ Kenneth E. Goodman Vice President, June 24, 1994 - - --------------------------- Finance Kenneth E. Goodman
DIRECTORS
/s/ George S. Cohan Director June 24, 1994 - - --------------------------- George S. Cohan
/s/William J. Candee, III Director June 24, 1994 - - --------------------------- William J. Candee, III
/s/ Dan L. Goldwasser Director June 24, 1994 - - --------------------------- Dan L. Goldwasser
/s/ Joseph Martin Schor Director June 24, 1994 - - -------------------------- Joseph Martin Schor
PAGE
	 REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
Forest Laboratories, Inc. New York, New York
The audits referred to in our report dated May 2, 1994 relating to the consolidated financial statements of Forest Laboratories, Inc. and Subsidiaries, which is incorporated in Item 8 of this Form 10-K by reference to the annual report to the shareholders for the year ended March 31, 1994, included the audits of the financial statement schedules listed in the accompanying index. These financial statement schedules are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statement schedules based upon our audits.
In our opinion, such financial statement schedules present fairly, in all material respects, the information set forth therein.
					 /s/ BDO Seidman 					 --------------------- 					 BDO Seidman
New York, New York May 2, 1994
				 S-1
								 SCHEDULE II
		 FOREST LABORATORIES, INC. AND SUBSIDIARIES
AMOUNTS RECEIVABLE FROM RELATED PARTIES AND UNDERWRITERS, PROMOTERS, AND 		 EMPLOYEES OTHER THAN RELATED PARTIES
				
				 					 Column D Column E 					 ------------------------------------- 							 Balance at end of Column A Column B Column C Deductions period - - ------------------------------------------------------------------------------- 		 Balance at (1) (2) (1) (2) 		 beginning Amounts Amounts Not Name of Debtor of period Additions collected written off Current Current - - -------------------------------------------------------------------------------
James A. McCabe -0- 150,000 25,000 -0- 125,000 -0-
					S-2
SCHEDULE VIII 				 			 FOREST LABORATORIES, INC. AND SUBSIDIARIES
				 VALUATION AND QUALIFYING ACCOUNTS
						 S-3
					
	 					 SCHEDULE X
		 FOREST LABORATORIES, INC. AND SUBSIDIARIES
		 SUPPLEMENTARY INCOME STATEMENT INFORMATION 									 	 Column A Column B - - --------------------------------- -------------------------------------- 	 Item Charged to costs and expenses - - --------------------------------- -------------------------------------- 			 			 Year ended March 31,
			 		 1994 1993 1992 					 ---- ---- ---- 1. Maintenance and repairs ..... (*) (*) (*)
2. Depreciation and amortization of intangible assets, pre- operating costs and similar deferrals .................. $ 6,915,000 $ 6,646,000 $6,730,000 	 =========== =========== ==========
3. Taxes, other than payroll and income taxes ........... (*) (*) (*)
4. Royalties ................... $14,972,000 $11,433,000 $8,754,000 	 =========== =========== ========== 5. Advertising costs ........... $16,265,000 $12,845,000 $8,377,000 				 =========== =========== ==========
(*) Amounts not in excess of 1% of net sales are not presented. 			 	 S-4
				
EXHIBIT 10.13
		 EQUITY SPLIT DOLLAR AGREEMENT
THIS AGREEMENT, made and entered into this 29th day of
March, 1994, by and among FOREST LABORATORIES, INC. a corporation
organized and existing under the laws of the State of Delaware
(hereinafter referred to as the "Corporation"), and Howard
Solomon (hereinafter referred to as the "Executive").
	 WHEREAS, the Executive has served as a senior executive
officer of the Corporation for more than the past 10 years; and
	 WHEREAS, the Corporation is desirous of retaining the
services of the Executive; and
	 WHEREAS, the Corporation is desirous of assisting the
Executive in paying for life insurance on his own life; and
	 WHEREAS, the Corporation has determined that this
assistance can best be provided under a "split-dollar"
arrangement; and
	 WHEREAS, the Executive or a trust established by the
Executive (the "Trust") has applied for, and is the owner and
beneficiary of Insurance Policy No. 77,684,850 (the "Policy")
issued by the Prudential Life Insurance Company ("Prudential") in
the face amount of $5,062,187; and
	 WHEREAS, the Corporation and the Executive agree to
make said insurance policy subject to this Split-Dollar
Agreement; and 	 PAGE
	 WHEREAS, the Executive has agreed to assign (or cause
the Trust to assign) the Policy to the Corporation as collateral
for amounts to be advanced by the Corporation under this
Agreement by an instrument of assignment, in form and substance
reasonably acceptable to the Corporation (the "Assignment"); and
	 WHEREAS, it is understood and agreed that this
split-dollar agreement is to be effective as of the date on which
the Policy is assigned to the Corporation;
	 NOW THEREFORE, for value received and in consideration
of the mutual covenants contained herein, the parties agree as
follows:
			 ARTICLE I - DEFINITIONS
	 For purposes of this Agreement, the following terms
will have the meanings set forth below:
	 1. "CASH SURRENDER VALUE OF THE POLICY" will mean the Cash Value of the Policy; plus the cash value of any paid-up additions; plus any dividend accumulations and unpaid dividends; and less any Policy Loan Balance.
	 2. "CASH VALUE OF THE POLICY" will mean the cash value as illustrated in the table of values shown in the Policy.
	 3. "CORPORATION'S INTEREST IN THE POLICY" will be as defined in Article VI.
	 4. "CURRENT LOAN VALUE OF THE POLICY" will mean the Loan Value of the Policy reduced by any outstanding Policy Loan Balance.
	 5. "LOAN VALUE OF THE POLICY" will mean the amount which, with loan interest, will equal the Cash Value
of the Policy and of any paid-up additions on the next loan interest due date or on the next premium due date whichever is the smaller amount.
	 6. "POLICY LOAN BALANCE" at any time will mean policy loans outstanding plus interest accrued to date.
	 7. "CORPORATION" shall be defined as Forest Laboratories, Inc. or any successor thereto.
	 8. "CHANGE OF CONTROL" shall be defined as:
	 A majority of members of the Corporation's Board of Directors (the "Board") are no longer appointees, nominees or designees of a majority of the members of the Board serving on the date hereof ("Continuing Directors") or members of the Board nominated, designated or appointed by Continuing Directors.
		 ARTICLE II - ALLOCATION OF PREMIUMS
	 The Executive will pay that portion of the annual
premium due on the Policy that is equal to the lesser of (a) the
amount of the entire economic benefit (including any economic
benefit attributable to the use of Policy dividends) that would
be taxable to the Executive but for such payment, or (b) the
amount of the premium due on the policy. The Corporation will
pay the remainder of the premium. The economic benefit that
would be taxable to the Executive will be computed in accordance
with applicable I.R.S. Revenue Rulings.
		 ARTICLE III - WAIVER OF PREMIUMS RIDER
	 If there is a rider on the Policy providing for the
waiver of premiums in the event of the Executive's disability,
any additional premium attributable to such rider will be payable
by the Corporation.
			 ARTICLE IV - OTHER RIDERS 			AND SUPPLEMENTAL AGREEMENTS
	 The Executive may add to the Policy one or more of
other riders or supplemental agreements which may be from time to
time available. Any additional premium attributable to such
rider or supplemental agreement will be payable by the Executive.
Any additional death benefits provided by such rider or
supplemental agreement will be paid to the beneficiary designated
by the Executive under the terms of the policy.
		 ARTICLE V - PAYMENT OF PREMIUMS
	 Any premium or portion thereof which is payable by the
Executive under any Article of this Agreement may at the election
of the Executive be deducted from the cash compensation otherwise
payable to him and the Corporation agrees to transmit that
premium or portion, along with any premium or portion thereof
payable by it, to Prudential on or before the premium due date.
		 ARTICLE VI - RIGHTS IN THE POLICY
	 The Executive may exercise all rights, options and
privileges of ownership in the Policy except those granted to the
Corporation by the Assignment. The Corporation will have those
rights in the Policy given to it by the Assignment except as
hereinafter modified. The Corporation will not surrender the
policy for cancellation except upon expiration of the thirty (30)
day period described in Article X. The Corporation will not,
without the written consent of the Executive, assign its rights
in the Policy, other than for the purpose of obtaining a loan
against the Policy, to anyone other than the Executive. The
Corporation will not take any action in dealing with Prudential
that would impair any right or interest of the Executive in the
Policy. The Corporation will have the right to borrow from
Prudential, and to secure that loan by the Policy, an amount
which, together with the unpaid interest accrued thereon, will at
no time exceed the lesser of (a) the Corporation's interest in
the Policy and (b) the Loan Value of the Policy. The
Corporation's Interest in the Policy will be the liability of the
Executive for which the Policy is held as collateral security
under the Assignment. "Corporation's Interest in the Policy"
will mean, at any time at which the value of such interest is to
be determined under this Agreement, the total of premiums
theretofore paid on the Policy by the Corporation (including
premiums paid by loans charged automatically against the Policy,
but not including any premiums paid, by loan or otherwise, for
any supplemental agreement or rider), reduced by the Policy Loan
Balance, with respect to any loan made or charged automatically
against the Policy by the Corporation. In the event that the
Corporation has paid additional premiums attributable to a rider
providing for the waiver of the premiums in the event of the
Executive's disability, "premiums" as used in the preceding
sentence will not include any premiums waived pursuant to the
terms of such rider while this Agreement is in force.
		 	 ARTICLE VII - RIGHTS 	 		 TO THE PROCEEDS AT DEATH
	 Upon the death of the Executive while this Agreement is
in force, the Corporation will, without delay, take whatever
action is necessary and required of it to collect the proceeds of
the Policy from Prudential. Upon collection of the Policy
proceeds, the Corporation will promptly pay the excess of the
Policy proceeds over the Corporation's Interest in the Policy to
the beneficiary designated by the Executive under the terms of
the Policy.
			 ARTICLE VIII - DISABILITY
	 If at any time the policy contains a rider providing
for the waiver of premiums in the event of the Executive's
disability, then, in the event of the Executive's Total
Disability, as defined in the rider, which begins while the rider
is in force and which continues for at least six months, the
Executive will pay to the Corporation the excess, if any, of the
Corporation's Interest in the Policy over the Current Loan Value
of the Policy and the Corporation will release its interest in
the Policy to the Executive. Upon release by the Corporation of
all of its interest in the Policy, the Executive will thereafter
own the Policy free from the Assignment and from this Agreement
but subject to any Policy loans and interest thereon.
	 	 ARTICLE IX - TERMINATION OF AGREEMENT
	 This Agreement may be terminated at any time while the
Insured is living with the agreement of the Corporation and the
Executive and, in any event, this Agreement will terminate upon
the later of twenty years from the date hereof or the date on
which the Corporation has recovered funds in respect of the
Policy equal to the Corporation's Interest in the Policy.
		 ARTICLE X - EXECUTIVE'S RIGHTS 			 UPON TERMINATION
10.1 The Corporation shall remain obligated to pay premiums due
under the Policy until the Policy is fully paid (as
defined below) notwithstanding the termination of
Executive's employment with the Corporation, however
caused. For purposes of this Agreement, the Policy shall
be deemed "fully paid" when the Policy's Cash Surrender
Value is sufficient to maintain the Policy in effect based
on current mortality and interest rate projections without
the payment of additional premiums at a time when the
Corporation has recovered an amount in respect of the
Policy equal to the Corporation's Interest in the Policy.
10.2 Except as otherwise provided for in Article IX or
Article X, Section 10.1, if the Termination of the
Executive's Employment is within two (2) years after a
Change of Control, the Corporation or any succeeding
corporation or organization will immediately deposit in to
the policy a lump sum cash payment, this sum calculated by
The Prudential, which will cause the policy to become
"fully paid" as defined in Section 10.1 but without regard
to the receiving by the Corporation of the Corporation's
Interest in the Policy. The Corporation further agrees
that it will make a second lump sum cash payment to the
Executive which will effectively allow the Executive to
make the then appropriate federal, state and city income
tax payments on the cash surrender value of the policy
transferred to the Executive. Upon a Change of Control
and the making of the two payments detailed above, the
terms of this Agreement will be deemed satisfied and this
Agreement will be deemed terminated.
		 ARTICLE XI - STATUS OF AGREEMENT 			VS. COLLATERAL ASSIGNMENT
	 As between the Executive and the Corporation, this
Agreement will take precedence over any provisions of the
Assignment. The Corporation agrees not to exercise any right
possessed by it under the Assignment except in conformity with
this Agreement.
	 	 ARTICLE XII - SATISFACTION OF CLAIM
	 The Executive's rights and interest, and rights and
interest of any persons taking under or through him, will be
completely satisfied upon compliance by the Corporation with the
provisions of this Agreement.
		 ARTICLE XIII - AMENDMENT AND ASSIGNMENT
	 This Agreement may be altered, amended or modified,
including the addition of any extra policy provisions, by a
written instrument signed by the Corporation and the Executive.
Either party may, subject to the limitations of Article VII,
assign its interest and obligations under this Agreement,
provided, however, that any assignment will be subject to the
terms of this Agreement.
		 ARTICLE XIV - POSSESSION OF POLICY
	 The Corporation will keep possession of the Policy.
The Corporation agrees from time to time to make the Policy
available to the Executive or the Prudential for the purpose of
endorsing or filing any change of beneficiary on the Policy but
the Policy will promptly be returned to the Corporation.
		 ARTICLE XV - MERGER; GOVERNING LAW
	 This Agreement sets forth the entire Agreement of the
parties hereto, and any and all prior agreements, to the extent
inconsistent herewith, are hereby superseded. This Agreement
will be governed by the laws of the State of New York.
		 ARTICLE XVI - INTERPRETATION
	 Where appropriate in this Agreement, words used in the
singular will include the plural and words used in the masculine
will include the feminine.
	 IN WITNESS WHEREOF, the parties have hereunto set their
hands and seals, the Corporation by its duly authorized officer,
in the day and year first above written.
		 ------------------------------------ (L.S.) 			 Howard Solomon
			 FOREST LABORATORIES, INC.
			 By: ____________________________
EXHIBIT 10.14
		 EQUITY SPLIT DOLLAR AGREEMENT
THIS AGREEMENT, made and entered into this 29th day of
March, 1994, by and among FOREST LABORATORIES, INC. a corporation
organized and existing under the laws of the State of Delaware
(hereinafter referred to as the "Corporation"), and Joseph M.
Schor (hereinafter referred to as the "Executive").
	 WHEREAS, the Executive has served as a senior executive
officer of the Corporation for more than the past 10 years; and
	 WHEREAS, the Corporation is desirous of retaining the
services of the Executive; and
	 WHEREAS, the Corporation is desirous of assisting the
Executive in paying for life insurance on his own life; and
	 WHEREAS, the Corporation has determined that this
assistance can best be provided under a "split-dollar"
arrangement; and
	 WHEREAS, the Executive or a trust established by the
Executive (the "Trust") has applied for, and is the owner and
beneficiary of Insurance Policy No. 77,684,845 (the "Policy")
issued by the Prudential Life Insurance Company ("Prudential") in
the face amount of $2,499,593; and
	 WHEREAS, the Corporation and the Executive agree to
make said insurance policy subject to this Split-Dollar
Agreement; and PAGE
	 WHEREAS, the Executive has agreed to assign (or cause
the Trust to assign) the Policy to the Corporation as collateral
for amounts to be advanced by the Corporation under this
Agreement by an instrument of assignment, in form and substance
reasonably acceptable to the Corporation (the "Assignment"); and
	 WHEREAS, it is understood and agreed that this
split-dollar agreement is to be effective as of the date on which
the Policy is assigned to the Corporation;
	 NOW THEREFORE, for value received and in consideration
of the mutual covenants contained herein, the parties agree as
follows:
			 ARTICLE I - DEFINITIONS
	 For purposes of this Agreement, the following terms
will have the meanings set forth below:
	 1. "CASH SURRENDER VALUE OF THE POLICY" will mean the Cash Value of the Policy; plus the cash value of any paid-up additions; plus any dividend accumulations and unpaid dividends; and less any Policy Loan Balance.
	 2. "CASH VALUE OF THE POLICY" will mean the cash value as illustrated in the table of values shown in the Policy.
	 3. "CORPORATION'S INTEREST IN THE POLICY" will be as defined in Article VI.
	 4. "CURRENT LOAN VALUE OF THE POLICY" will mean the Loan Value of the Policy reduced by any outstanding Policy Loan Balance.
	 5. "LOAN VALUE OF THE POLICY" will mean the amount which, with loan interest, will equal the Cash Value 				
of the Policy and of any paid-up additions on the next loan interest due date or on the next premium due date whichever is the smaller amount.
	 6. "POLICY LOAN BALANCE" at any time will mean policy loans outstanding plus interest accrued to date.
	 7. "CORPORATION" shall be defined as Forest Laboratories, Inc. or any successor thereto.
	 8. "CHANGE OF CONTROL" shall be defined as:
	 A majority of members of the Corporation's Board of Directors (the "Board") are no longer appointees, nominees or designees of a majority of the members of the Board serving on the date hereof ("Continuing Directors") or members of the Board nominated, designated or appointed by Continuing Directors.
		 ARTICLE II - ALLOCATION OF PREMIUMS
	 The Executive will pay that portion of the annual
premium due on the Policy that is equal to the lesser of (a) the
amount of the entire economic benefit (including any economic
benefit attributable to the use of Policy dividends) that would
be taxable to the Executive but for such payment, or (b) the
amount of the premium due on the policy. The Corporation will
pay the remainder of the premium. The economic benefit that
would be taxable to the Executive will be computed in accordance
with applicable I.R.S. Revenue Rulings.
		 ARTICLE III - WAIVER OF PREMIUMS RIDER
	 If there is a rider on the Policy providing for the
waiver of premiums in the event of the Executive's disability,
any additional premium attributable to such rider will be payable
by the Corporation.
			 ARTICLE IV - OTHER RIDERS 			AND SUPPLEMENTAL AGREEMENTS
	 The Executive may add to the Policy one or more of
other riders or supplemental agreements which may be from time to
time available. Any additional premium attributable to such
rider or supplemental agreement will be payable by the Executive.
Any additional death benefits provided by such rider or
supplemental agreement will be paid to the beneficiary designated
by the Executive under the terms of the policy.
		 ARTICLE V - PAYMENT OF PREMIUMS
	 Any premium or portion thereof which is payable by the
Executive under any Article of this Agreement may at the election
of the Executive be deducted from the cash compensation otherwise
payable to him and the Corporation agrees to transmit that
premium or portion, along with any premium or portion thereof
payable by it, to Prudential on or before the premium due date. 		 	 	 ARTICLE VI - RIGHTS IN THE POLICY
	 The Executive may exercise all rights, options and
privileges of ownership in the Policy except those granted to the
Corporation by the Assignment. The Corporation will have those
rights in the Policy given to it by the Assignment except as
hereinafter modified. The Corporation will not surrender the
policy for cancellation except upon expiration of the thirty (30)
day period described in Article X. The Corporation will not,
without the written consent of the Executive, assign its rights
in the Policy, other than for the purpose of obtaining a loan
against the Policy, to anyone other than the Executive. The
Corporation will not take any action in dealing with Prudential
that would impair any right or interest of the Executive in the
Policy. The Corporation will have the right to borrow from
Prudential, and to secure that loan by the Policy, an amount
which, together with the unpaid interest accrued thereon, will at
no time exceed the lesser of (a) the Corporation's interest in
the Policy and (b) the Loan Value of the Policy. The
Corporation's Interest in the Policy will be the liability of the
Executive for which the Policy is held as collateral security
under the Assignment. "Corporation's Interest in the Policy"
ill mean, at any time at which the value of such interest is to
be determined under this Agreement, the total of premiums
theretofore paid on the Policy by the Corporation (including
premiums paid by loans charged automatically against the Policy,
but not including any premiums paid, by loan or otherwise, for
any supplemental agreement or rider), reduced by the Policy Loan
Balance, with respect to any loan made or charged automatically
against the Policy by the Corporation. In the event that the
Corporation has paid additional premiums attributable to a rider
providing for the waiver of the premiums in the event of the
Executive's disability, "premiums" as used in the preceding
sentence will not include any premiums waived pursuant to the
terms of such rider while this Agreement is in force.
			 ARTICLE VII - RIGHTS 			 TO THE PROCEEDS AT DEATH
	 Upon the death of the Executive while this Agreement is
in force, the Corporation will, without delay, take whatever
action is necessary and required of it to collect the proceeds of
the Policy from Prudential. Upon collection of the Policy
proceeds, the Corporation will promptly pay the excess of the
Policy proceeds over the Corporation's Interest in the Policy to
the beneficiary designated by the Executive under the terms of
the Policy.
	 		 ARTICLE VIII - DISABILITY
	 If at any time the policy contains a rider providing
for the waiver of premiums in the event of the Executive's
disability, then, in the event of the Executive's Total
Disability, as defined in the rider, which begins while the rider
is in force and which continues for at least six months, the
Executive will pay to the Corporation the excess, if any, of the
Corporation's Interest in the Policy over the Current Loan Value 				
of the Policy and the Corporation will release its interest in
the Policy to the Executive. Upon release by the Corporation of
all of its interest in the Policy, the Executive will thereafter
own the Policy free from the Assignment and from this Agreement
but subject to any Policy loans and interest thereon.
		 ARTICLE IX - TERMINATION OF AGREEMENT
	 This Agreement may be terminated at any time while the
Insured is living with the agreement of the Corporation and the
Executive and, in any event, this Agreement will terminate upon
the later of twenty years from the date hereof or the date on
which the Corporation has recovered funds in respect of the
Policy equal to the Corporation's Interest in the Policy.
		 ARTICLE X - EXECUTIVE'S RIGHTS 			 UPON TERMINATION
10.1 The Corporation shall remain obligated to pay premiums due
under the Policy until the Policy is fully paid (as
defined below) notwithstanding the termination of
Executive's employment with the Corporation, however
caused. For purposes of this Agreement, the Policy shall
be deemed "fully paid" when the Policy's Cash Surrender
Value is sufficient to maintain the Policy in effect based
on current mortality and interest rate projections without
the payment of additional premiums at a time when the
Corporation has recovered an amount in respect of the
Policy equal to the Corporation's Interest in the Policy.
10.2 Except as otherwise provided for in Article IX or
Article X, Section 10.1, if the Termination of the
Executive's Employment is within two (2) years after a
Change of Control, the Corporation or any succeeding
corporation or organization will immediately deposit in to
the policy a lump sum cash payment, this sum calculated by
The Prudential, which will cause the policy to become
"fully paid" as defined in Section 10.1 but without regard
to the receiving by the Corporation of the Corporation's
Interest in the Policy. The Corporation further agrees
that it will make a second lump sum cash payment to the
Executive which will effectively allow the Executive to
make the then appropriate federal, state and city income
tax payments on the cash surrender value of the policy
transferred to the Executive. Upon a Change of Control
and the making of the two payments detailed above, the
terms of this Agreement will be deemed satisfied and this
Agreement will be deemed terminated.
		 ARTICLE XI - STATUS OF AGREEMENT 			VS. COLLATERAL ASSIGNMENT
	 As between the Executive and the Corporation, this
Agreement will take precedence over any provisions of the
Assignment. The Corporation agrees not to exercise any right
possessed by it under the Assignment except in conformity with
this Agreement.
		 ARTICLE XII - SATISFACTION OF CLAIM
	 The Executive's rights and interest, and rights and
interest of any persons taking under or through him, will be
completely satisfied upon compliance by the Corporation with the
provisions of this Agreement.
		 ARTICLE XIII - AMENDMENT AND ASSIGNMENT
	 This Agreement may be altered, amended or modified,
including the addition of any extra policy provisions, by a
written instrument signed by the Corporation and the Executive.
Either party may, subject to the limitations of Article VII,
assign its interest and obligations under this Agreement,
provided, however, that any assignment will be subject to the
terms of this Agreement.
	 ARTICLE XIV - POSSESSION OF POLICY
	 The Corporation will keep possession of the Policy.
The Corporation agrees from time to time to make the Policy
available to the Executive or the Prudential for the purpose of
endorsing or filing any change of beneficiary on the Policy but
the Policy will promptly be returned to the Corporation.
		 ARTICLE XV - MERGER; GOVERNING LAW
	 This Agreement sets forth the entire Agreement of the
parties hereto, and any and all prior agreements, to the extent
inconsistent herewith, are hereby superseded. This Agreement
will be governed by the laws of the State of New York.
ARTICLE XVI - INTERPRETATION
	 Where appropriate in this Agreement, words used in the
singular will include the plural and words used in the masculine
will include the feminine.
	 IN WITNESS WHEREOF, the parties have hereunto set their
hands and seals, the Corporation by its duly authorized officer,
in the day and year first above written.
			 __________________________________(L.S.) 				 Joseph M. Schor
	 FOREST LABORATORIES, INC.
			 By: ______________________________
EXHIBIT 10.15
		 EQUITY SPLIT DOLLAR AGREEMENT
THIS AGREEMENT, made and entered into this 29th day of
March, 1994, by and among FOREST LABORATORIES, INC. a corporation
organized and existing under the laws of the State of Delaware
(hereinafter referred to as the "Corporation"), and Phillip M.
Satow (hereinafter referred to as the "Executive").
	 WHEREAS, the Executive has served as a senior executive
officer of the Corporation for more than the past 9 years; and
	 WHEREAS, the Corporation is desirous of retaining the
services of the Executive; and
	 WHEREAS, the Corporation is desirous of assisting the
Executive in paying for life insurance on his own life; and
	 WHEREAS, the Corporation has determined that this
assistance can best be provided under a "split-dollar"
arrangement; and
	 WHEREAS, the Executive or a trust established by the
Executive (the "Trust") has applied for, and is the owner and
beneficiary of Insurance Policy No. 77,684,830 (the "Policy")
issued by the Prudential Life Insurance Company ("Prudential") in
the face amount of $2,372,584; and
	 WHEREAS, the Corporation and the Executive agree to
make said insurance policy subject to this Split-Dollar
Agreement; and PAGE
	 WHEREAS, the Executive has agreed to assign (or cause
the Trust to assign) the Policy to the Corporation as collateral
for amounts to be advanced by the Corporation under this
Agreement by an instrument of assignment, in form and substance
reasonably acceptable to the Corporation (the "Assignment"); and
	 WHEREAS, it is understood and agreed that this
split-dollar agreement is to be effective as of the date on which
the Policy is assigned to the Corporation;
	 NOW THEREFORE, for value received and in consideration
of the mutual covenants contained herein, the parties agree as
follows:
			 ARTICLE I - DEFINITIONS
	 For purposes of this Agreement, the following terms
will have the meanings set forth below:
	 1. "CASH SURRENDER VALUE OF THE POLICY" will mean the Cash Value of the Policy; plus the cash value of any paid-up additions; plus any dividend accumulations and unpaid dividends; and less any Policy Loan Balance.
	 2. "CASH VALUE OF THE POLICY" will mean the cash value as illustrated in the table of values shown in the Policy.
	 3. "CORPORATION'S INTEREST IN THE POLICY" will be as defined in Article VI.
	 4. "CURRENT LOAN VALUE OF THE POLICY" will mean the Loan Value of the Policy reduced by any outstanding Policy Loan Balance.
	 5. "LOAN VALUE OF THE POLICY" will mean the amount which, with loan interest, will equal the Cash Value
of the Policy and of any paid-up additions on the next loan interest due date or on the next premium due date whichever is the smaller amount.
	 6. "POLICY LOAN BALANCE" at any time will mean policy loans outstanding plus interest accrued to date.
	 7. "CORPORATION" shall be defined as Forest Laboratories, Inc. or any successor thereto.
	 8. "CHANGE OF CONTROL" shall be defined as:
	 A majority of members of the Corporation's Board of Directors (the "Board") are no longer appointees, nominees or designees of a majority of the members of the Board serving on the date hereof ("Continuing Directors") or members of the Board nominated, designated or appointed by Continuing Directors.
	 ARTICLE II - ALLOCATION OF PREMIUMS
	 The Executive will pay that portion of the annual
premium due on the Policy that is equal to the lesser of (a) the
amount of the entire economic benefit (including any economic
benefit attributable to the use of Policy dividends) that would
be taxable to the Executive but for such payment, or (b) the
amount of the premium due on the policy. The Corporation will
pay the remainder of the premium. The economic benefit that
would be taxable to the Executive will be computed in accordance
with applicable I.R.S. Revenue Rulings.
		 ARTICLE III - WAIVER OF PREMIUMS RIDER
	 If there is a rider on the Policy providing for the
waiver of premiums in the event of the Executive's disability,
any additional premium attributable to such rider will be payable
by the Corporation.
			 ARTICLE IV - OTHER RIDERS 			AND SUPPLEMENTAL AGREEMENTS
	 The Executive may add to the Policy one or more of
other riders or supplemental agreements which may be from time to
time available. Any additional premium attributable to such
rider or supplemental agreement will be payable by the Executive.
Any additional death benefits provided by such rider or
supplemental agreement will be paid to the beneficiary designated
by the Executive under the terms of the policy.
		 ARTICLE V - PAYMENT OF PREMIUMS
	 Any premium or portion thereof which is payable by the
Executive under any Article of this Agreement may at the election
of the Executive be deducted from the cash compensation otherwise
payable to him and the Corporation agrees to transmit that
premium or portion, along with any premium or portion thereof
payable by it, to Prudential on or before the premium due date.
		 ARTICLE VI - RIGHTS IN THE POLICY
	 The Executive may exercise all rights, options and
privileges of ownership in the Policy except those granted to the
Corporation by the Assignment. The Corporation will have those
rights in the Policy given to it by the Assignment except as
hereinafter modified. The Corporation will not surrender the
policy for cancellation except upon expiration of the thirty (30)
day period described in Article X. The Corporation will not,
without the written consent of the Executive, assign its rights
in the Policy, other than for the purpose of obtaining a loan
against the Policy, to anyone other than the Executive. The
Corporation will not take any action in dealing with Prudential
that would impair any right or interest of the Executive in the
Policy. The Corporation will have the right to borrow from
Prudential, and to secure that loan by the Policy, an amount
which, together with the unpaid interest accrued thereon, will at
no time exceed the lesser of (a) the Corporation's interest in
the Policy and (b) the Loan Value of the Policy. The
Corporation's Interest in the Policy will be the liability of the
Executive for which the Policy is held as collateral security
under the Assignment. "Corporation's Interest in the Policy"
will mean, at any time at which the value of such interest is to
be determined under this Agreement, the total of premiums
theretofore paid on the Policy by the Corporation (including
premiums paid by loans charged automatically against the Policy,
but not including any premiums paid, by loan or otherwise, for
any supplemental agreement or rider), reduced by the Policy Loan
Balance, with respect to any loan made or charged automatically
against the Policy by the Corporation. In the event that the
Corporation has paid additional premiums attributable to a rider
providing for the waiver of the premiums in the event of the
Executive's disability, "premiums" as used in the preceding
sentence will not include any premiums waived pursuant to the
terms of such rider while this Agreement is in force.
	 		 ARTICLE VII - RIGHTS 		 	 TO THE PROCEEDS AT DEATH
	 Upon the death of the Executive while this Agreement is
in force, the Corporation will, without delay, take whatever
action is necessary and required of it to collect the proceeds of
the Policy from Prudential. Upon collection of the Policy
proceeds, the Corporation will promptly pay the excess of the
Policy proceeds over the Corporation's Interest in the Policy to
the beneficiary designated by the Executive under the terms of
the Policy.
			 ARTICLE VIII - DISABILITY
	 If at any time the policy contains a rider providing
for the waiver of premiums in the event of the Executive's
disability, then, in the event of the Executive's Total
Disability, as defined in the rider, which begins while the rider
is in force and which continues for at least six months, the
Executive will pay to the Corporation the excess, if any, of the
Corporation's Interest in the Policy over the Current Loan Value
of the Policy and the Corporation will release its interest in
the Policy to the Executive. Upon release by the Corporation of
all of its interest in the Policy, the Executive will thereafter
own the Policy free from the Assignment and from this Agreement
but subject to any Policy loans and interest thereon.
		 ARTICLE IX - TERMINATION OF AGREEMENT
	 This Agreement may be terminated at any time while the
Insured is living with the agreement of the Corporation and the
Executive and, in any event, this Agreement will terminate upon
the later of twenty years from the date hereof or the date on
which the Corporation has recovered funds in respect of the
Policy equal to the Corporation's Interest in the Policy.
		 ARTICLE X - EXECUTIVE'S RIGHTS 			 UPON TERMINATION
10.1 The Corporation shall remain obligated to pay premiums due
under the Policy until the Policy is fully paid (as
defined below) notwithstanding the termination of
Executive's employment with the Corporation, however
caused. For purposes of this Agreement, the Policy shall
be deemed "fully paid" when the Policy's Cash Surrender
Value is sufficient to maintain the Policy in effect based
on current mortality and interest rate projections without
the payment of additional premiums at a time when the
Corporation has recovered an amount in respect of the
Policy equal to the Corporation's Interest in the Policy.
10.2 Except as otherwise provided for in Article IX or
Article X, Section 10.1, if the Termination of the
Executive's Employment is within two (2) years after a
Change of Control, the Corporation or any succeeding
corporation or organization will immediately deposit in to
the policy a lump sum cash payment, this sum calculated by
The Prudential, which will cause the policy to become
"fully paid" as defined in Section 10.1 but without regard
to the receiving by the Corporation of the Corporation's
Interest in the Policy. The Corporation further agrees
that it will make a second lump sum cash payment to the
Executive which will effectively allow the Executive to
make the then appropriate federal, state and city income
tax payments on the cash surrender value of the policy
transferred to the Executive. Upon a Change of Control
and the making of the two payments detailed above, the
terms of this Agreement will be deemed satisfied and this
Agreement will be deemed terminated.
	 	 ARTICLE XI - STATUS OF AGREEMENT 			VS. COLLATERAL ASSIGNMENT
	 As between the Executive and the Corporation, this
Agreement will take precedence over any provisions of the
Assignment. The Corporation agrees not to exercise any right
possessed by it under the Assignment except in conformity with
this Agreement.
		 ARTICLE XII - SATISFACTION OF CLAIM
	 The Executive's rights and interest, and rights and
interest of any persons taking under or through him, will be
completely satisfied upon compliance by the Corporation with the
provisions of this Agreement.
		 ARTICLE XIII - AMENDMENT AND ASSIGNMENT
	 This Agreement may be altered, amended or modified,
including the addition of any extra policy provisions, by a
written instrument signed by the Corporation and the Executive.
Either party may, subject to the limitations of Article VII,
assign its interest and obligations under this Agreement,
provided, however, that any assignment will be subject to the
terms of this Agreement.
		 ARTICLE XIV - POSSESSION OF POLICY
	 The Corporation will keep possession of the Policy.
The Corporation agrees from time to time to make the Policy
available to the Executive or the Prudential for the purpose of
endorsing or filing any change of beneficiary on the Policy but
the Policy will promptly be returned to the Corporation.
		 ARTICLE XV - MERGER; GOVERNING LAW
	 This Agreement sets forth the entire Agreement of the
parties hereto, and any and all prior agreements, to the extent
inconsistent herewith, are hereby superseded. This Agreement
will be governed by the laws of the State of New York.
		 ARTICLE XVI - INTERPRETATION
	 Where appropriate in this Agreement, words used in the
singular will include the plural and words used in the masculine
will include the feminine.
	 IN WITNESS WHEREOF, the parties have hereunto set their
hands and seals, the Corporation by its duly authorized officer,
in the day and year first above written.
			______________________________________ (L.S.) 		 		 Phillip M. Satow
			 FOREST LABORATORIES, INC.
			 By: ________________________________
EXHIBIT 10.16
		 EQUITY SPLIT DOLLAR AGREEMENT
THIS AGREEMENT, made and entered into this 29th day of
March, 1994, by and among FOREST LABORATORIES, INC. a corporation
organized and existing under the laws of the State of Delaware
(hereinafter referred to as the "Corporation"), and Kenneth E.
Goodman (hereinafter referred to as the "Executive").
	 WHEREAS, the Executive has served as a senior executive
officer of the Corporation for more than the past 10 years; and
	 WHEREAS, the Corporation is desirous of retaining the
services of the Executive; and
	 WHEREAS, the Corporation is desirous of assisting the
Executive in paying for life insurance on his own life; and
	 WHEREAS, the Corporation has determined that this
assistance can best be provided under a "split-dollar"
arrangement; and
	 WHEREAS, the Executive or a trust established by the
Executive (the "Trust") has applied for, and is the owner and
beneficiary of Insurance Policy No. 77,684,852 (the "Policy")
issued by the Prudential Life Insurance Company ("Prudential") in
the face amount of $2,297,917; and
	 WHEREAS, the Corporation and the Executive agree to
make said insurance policy subject to this Split-Dollar
Agreement; and PAGE
	 WHEREAS, the Executive has agreed to assign (or cause
the Trust to assign) the Policy to the Corporation as collateral
for amounts to be advanced by the Corporation under this
Agreement by an instrument of assignment, in form and substance
reasonably acceptable to the Corporation (the "Assignment"); and
	 WHEREAS, it is understood and agreed that this
split-dollar agreement is to be effective as of the date on which
the Policy is assigned to the Corporation;
	 NOW THEREFORE, for value received and in consideration
of the mutual covenants contained herein, the parties agree as
follows:
	 		 ARTICLE I - DEFINITIONS
	 For purposes of this Agreement, the following terms
will have the meanings set forth below:
	 1. "Cash Surrender Value of the Policy" will mean the Cash Value of the Policy; plus the cash value of any paid-up additions; plus any dividend accumulations and unpaid dividends; and less any Policy Loan Balance.
	 2. "Cash Value of the Policy" will mean the cash value as illustrated in the table of values shown in the Policy.
	 3. "Corporation's Interest in the Policy" will be as defined in Article VI.
	 4. "Current Loan Value of the Policy" will mean the Loan Value of the Policy reduced by any outstanding Policy Loan Balance.
	 5. "Loan Value of the Policy" will mean the amount which, with loan interest, will equal the Cash Value
of the Policy and of any paid-up additions on the next loan interest due date or on the next premium due date whichever is the smaller amount.
	 6. "Policy Loan Balance" at any time will mean policy loans outstanding plus interest accrued to date.
	 7. "Corporation" shall be defined as Forest Laboratories, Inc. or any successor thereto.
	 8. "Change of Control" shall be defined as:
	 A majority of members of the Corporation's Board of Directors (the "Board") are no longer appointees, nominees or designees of a majority of the members of the Board serving on the date hereof ("Continuing Directors") or members of the Board nominated, designated or appointed by Continuing Directors.
		 ARTICLE II - ALLOCATION OF PREMIUMS
	 The Executive will pay that portion of the annual
premium due on the Policy that is equal to the lesser of (a) the
amount of the entire economic benefit (including any economic
benefit attributable to the use of Policy dividends) that would
be taxable to the Executive but for such payment, or (b) the
amount of the premium due on the policy. The Corporation will
pay the remainder of the premium. The economic benefit that
would be taxable to the Executive will be computed in accordance
with applicable I.R.S. Revenue Rulings.
		 ARTICLE III - WAIVER OF PREMIUMS RIDER
	 If there is a rider on the Policy providing for the
waiver of premiums in the event of the Executive's disability,
any additional premium attributable to such rider will be payable
by the Corporation.
			 ARTICLE IV - OTHER RIDERS 			AND SUPPLEMENTAL AGREEMENTS
	 The Executive may add to the Policy one or more of
other riders or supplemental agreements which may be from time to
time available. Any additional premium attributable to such
rider or supplemental agreement will be payable by the Executive.
Any additional death benefits provided by such rider or
supplemental agreement will be paid to the beneficiary designated
by the Executive under the terms of the policy.
	 ARTICLE V - PAYMENT OF PREMIUMS
	 Any premium or portion thereof which is payable by the
Executive under any Article of this Agreement may at the election
of the Executive be deducted from the cash compensation otherwise
payable to him and the Corporation agrees to transmit that
premium or portion, along with any premium or portion thereof
payable by it, to Prudential on or before the premium due date.
		 ARTICLE VI - RIGHTS IN THE POLICY
	 The Executive may exercise all rights, options and
privileges of ownership in the Policy except those granted to the
Corporation by the Assignment. The Corporation will have those
rights in the Policy given to it by the Assignment except as
hereinafter modified. The Corporation will not surrender the
policy for cancellation except upon expiration of the thirty (30)
day period described in Article X. The Corporation will not,
without the written consent of the Executive, assign its rights
in the Policy, other than for the purpose of obtaining a loan
against the Policy, to anyone other than the Executive. The
Corporation will not take any action in dealing with Prudential
that would impair any right or interest of the Executive in the
Policy. The Corporation will have the right to borrow from
Prudential, and to secure that loan by the Policy, an amount
which, together with the unpaid interest accrued thereon, will at
no time exceed the lesser of (a) the Corporation's interest in
the Policy and (b) the Loan Value of the Policy. The
Corporation's Interest in the Policy will be the liability of the
Executive for which the Policy is held as collateral security
under the Assignment. "Corporation's Interest in the Policy"
will mean, at any time at which the value of such interest is to
be determined under this Agreement, the total of premiums
theretofore paid on the Policy by the Corporation (including
premiums paid by loans charged automatically against the Policy,
but not including any premiums paid, by loan or otherwise, for
any supplemental agreement or rider), reduced by the Policy Loan
Balance, with respect to any loan made or charged automatically
against the Policy by the Corporation. In the event that the
Corporation has paid additional premiums attributable to a rider
providing for the waiver of the premiums in the event of the
Executive's disability, "premiums" as used in the preceding
sentence will not include any premiums waived pursuant to the
terms of such rider while this Agreement is in force.
			 ARTICLE VII - RIGHTS 			 TO THE PROCEEDS AT DEATH
	 Upon the death of the Executive while this Agreement is
in force, the Corporation will, without delay, take whatever
action is necessary and required of it to collect the proceeds of
the Policy from Prudential. Upon collection of the Policy
proceeds, the Corporation will promptly pay the excess of the
Policy proceeds over the Corporation's Interest in the Policy to
the beneficiary designated by the Executive under the terms of
the Policy.
			 ARTICLE VIII - DISABILITY
	 If at any time the policy contains a rider providing
for the waiver of premiums in the event of the Executive's
disability, then, in the event of the Executive's Total
Disability, as defined in the rider, which begins while the rider
is in force and which continues for at least six months, the
Executive will pay to the Corporation the excess, if any, of the
Corporation's Interest in the Policy over the Current Loan Value
of the Policy and the Corporation will release its interest in
the Policy to the Executive. Upon release by the Corporation of
all of its interest in the Policy, the Executive will thereafter
own the Policy free from the Assignment and from this Agreement
but subject to any Policy loans and interest thereon.
		 ARTICLE IX - TERMINATION OF AGREEMENT
	 This Agreement may be terminated at any time while the
Insured is living with the agreement of the Corporation and the
Executive and, in any event, this Agreement will terminate upon
the later of twenty years from the date hereof or the date on
which the Corporation has recovered funds in respect of the
Policy equal to the Corporation's Interest in the Policy.
		 ARTICLE X - EXECUTIVE'S RIGHTS 			 UPON TERMINATION
10.1 The Corporation shall remain obligated to pay premiums due
under the Policy until the Policy is fully paid (as
defined below) notwithstanding the termination of
Executive's employment with the Corporation, however
caused. For purposes of this Agreement, the Policy shall
be deemed "fully paid" when the Policy's Cash Surrender
Value is sufficient to maintain the Policy in effect based
on current mortality and interest rate projections without
the payment of additional premiums at a time when the
Corporation has recovered an amount in respect of the
Policy equal to the Corporation's Interest in the Policy.
10.2 Except as otherwise provided for in Article IX or
Article X, Section 10.1, if the Termination of the
Executive's Employment is within two (2) years after a
Change of Control, the Corporation or any succeeding
corporation or organization will immediately deposit in to
the policy a lump sum cash payment, this sum calculated by
The Prudential, which will cause the policy to become
"fully paid" as defined in Section 10.1 but without regard
to the receiving by the Corporation of the Corporation's
Interest in the Policy. The Corporation further agrees
that it will make a second lump sum cash payment to the
Executive which will effectively allow the Executive to
make the then appropriate federal, state and city income
tax payments on the cash surrender value of the policy
transferred to the Executive. Upon a Change of Control
and the making of the two payments detailed above, the
terms of this Agreement will be deemed satisfied and this
Agreement will be deemed terminated.
		 ARTICLE XI - STATUS OF AGREEMENT 			VS. COLLATERAL ASSIGNMENT
	 As between the Executive and the Corporation, this
Agreement will take precedence over any provisions of the
Assignment. The Corporation agrees not to exercise any right
possessed by it under the Assignment except in conformity with
this Agreement.
		 ARTICLE XII - SATISFACTION OF CLAIM
	 The Executive's rights and interest, and rights and
interest of any persons taking under or through him, will be
completely satisfied upon compliance by the Corporation with the
provisions of this Agreement.
		 ARTICLE XIII - AMENDMENT AND ASSIGNMENT
	 This Agreement may be altered, amended or modified,
including the addition of any extra policy provisions, by a
written instrument signed by the Corporation and the Executive.
Either party may, subject to the limitations of Article VII,
assign its interest and obligations under this Agreement,
provided, however, that any assignment will be subject to the
terms of this Agreement.
		 ARTICLE XIV - POSSESSION OF POLICY
	 The Corporation will keep possession of the Policy.
The Corporation agrees from time to time to make the Policy
available to the Executive or the Prudential for the purpose of
endorsing or filing any change of beneficiary on the Policy but
the Policy will promptly be returned to the Corporation.
	 	 ARTICLE XV - MERGER; GOVERNING LAW
	 This Agreement sets forth the entire Agreement of the
parties hereto, and any and all prior agreements, to the extent
inconsistent herewith, are hereby superseded. This Agreement
will be governed by the laws of the State of New York.
		 ARTICLE XVI - INTERPRETATION
	 Where appropriate in this Agreement, words used in the
singular will include the plural and words used in the masculine
will include the feminine.
	 IN WITNESS WHEREOF, the parties have hereunto set their
hands and seals, the Corporation by its duly authorized officer,
in the day and year first above written.
____________________________________(L.S.) 				Kenneth E. Goodman
			 FOREST LABORATORIES, INC.
			 By: _______________________________
				 EXHIBIT 13
QUARTERLY STOCK MARKET PRICES
					 High Low ____________________________________________________________________________ April-June 1992 34 7/8 30 - - ---------------------------------------------------------------------------- July-September 1992 40 3/8 30 3/4 - - ---------------------------------------------------------------------------- October-December 1992 44 7/8 30 3/4 - - ---------------------------------------------------------------------------- January-March 1993 43 1/4 27 1/2 - - ---------------------------------------------------------------------------- April-June 1993 38 1/2 31 1/2 - - ---------------------------------------------------------------------------- July-September 1993 37 7/8 28 1/4 - - ---------------------------------------------------------------------------- October-December 1993 47 7/8 37 3/8 - - ---------------------------------------------------------------------------- January-March 1994 52 1/2 41 1/2 - - ----------------------------------------------------------------------------
As of June 3, 1994 there were 3,211 stockholders of record of the Company's common stock.
SELECTED FINANCIAL DATA
No dividends were paid on common shares during the period. PAGE
SELECTED FINANCIAL DATA
A. Net income per share was computed by dividing net income by the weighted average number of common and common equivalent shares during each year. All amounts give effect to the February 1991 100% stock dividend. Common equivalent shares consist of unissued shares under options and included to the extent that they have a dilutive effect. Fully dilutednet income per share is presented because of an increase in the dilutive effect of stock options (method) which resulted from the higher price of the Company's stock at the end of the year as compared with the average price during the year. The weighted average number of common and common equivalent shares outstanding for 1994 was computed as follows:
PAGE
FOREST LABORATORIES, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following comments should be read in conjunction with the Consolidated Financial Statements and Notes contained therein:
FINANCIAL CONDITION AND LIQUIDITY Net current assets increased by $21,826,000 in fiscal 1994. The increase, due principally to increases in cash and accounts receivable, resulted from the increases in sales and profits due to the continuing growth of the Company's branded promoted products, specialty controlled release generic products and the launch, during the third quarter, of Flumadine-R-. Long-term marketable securities increased as a result of the Company reinvesting a portion of its cash in securities maturing over a period of one to two years. Such securities are expected to increase the Company's yield on investments as compared to the short-term securities which they replaced. License agreements and other intangible assets increased primarily due to the final payment on the acquisition of worldwide rights to the product Flumadine. Other assets increased mostly as a result of a payment made to extinguish future royalty obligations related to the purchase of Flumadine. Deferred income taxes-current increased while non-current deferred income taxes decreased due principally to the utilization of tax benefit carryforwards recorded during fiscal 1993.
Property, plant and equipment increased during fiscal 1994 principally from the expansion of the Company's United States and Irish facilities in order to meet increased demand for the Company's products. The expansion will continue in fiscal 1995 in order to adequately meet the Company's needs for the manufacturing, warehousing and distribution of its existing and future products. Management believes that current cash levels, coupled with funds to be generated by on-going operations, will sufficiently support these capital expenditures and should facilitate potential acquisitions of products or companies.
RESULTS OF OPERATIONS Net sales increased in 1994 by $66,277,000 as a result of the continued strong growth of the Company's branded promoted products, specialty controlled release generic products and the introduction of Flumadine. Net volume growth of the Company's principal promoted and generic product lines accounted for $46,103,000 of the increase. Flumadine sales during fiscal 1994 amounted to $21,660,000. Sales volume of the Company's older unpromoted product lines increased by $2,384,000, while foreign exchange translation rate declines reduced net sales by $5,936,000. The remainder of the net sales increase was attributed to price increases. Net sales for fiscal 1993 increased by $46,171,000 as compared with fiscal 1992. Volume growth of the Company's principal promoted and generic product lines, including the introduction, during 1993, of two new product line extensions, accounted for $45,982,000 of the increase. Sales decreases of the Company's older unpromoted product lines amounted to $9,925,000. The remainder of the net sales increase was attributed to price increases.
		 FOREST LABORATORIES, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (CONTINUED)
Other income decreased $1,390,000 during fiscal 1994 as a result of lower commission income and interest income. The lower commission income resulted from the termination, during the third quarter of fiscal 1993, of a joint marketing agreement with Rorer Pharmaceuticals, Inc. for the product DDAVP-R- . Interest income decreased due to the maturing of long-term bonds of the Commonwealth of Puerto Rico and lower interest rates in the United States. The increase in other income in fiscal 1993 as compared to 1992 was principally the result of higher commission income pursuant to the Company's joint marketing agreements with other pharmaceutical companies.
Cost of sales as a percentage of sales decreased to 18% in 1994 from 19% in 1993 and 20% in 1992 due to changes in product mix and volume and price increases.
Selling, general and administrative expense increased by $25,587,000 during 1994. The increase is principally attributed to the continued growth of the Company's salesforce efforts ($4,645,000), and marketing activities ($19,762,000) related to the Company's principal promoted and generic product lines, including the launch of Flumadine. The increase in selling, general and administrative expense of $16,872,000 in fiscal 1993 as compared to 1992 resulted primarily from the Company's salesforce efforts and marketing activities related to the Company's principal promoted products, including the introduction of two product line extensions.
Interest expense of $1,957,000 in fiscal 1993 and $3,706,000 in 1992 was the result of the debt incurred in connection with the purchase of a line of thyroid products. The debt was repaid during fiscal 1993 and no further interest expense is being incurred. 					 Research and development increased by $5,944,000 during fiscal 1994 and $4,283,000 in 1993 as a result of the cost of conducting clinical studies in order to obtain approval of new products and the cost of developing products using the Company's controlled release technology. During fiscal 1994, there was particular emphasis on Synapton-TM- and Monurol-R-. Synapton, is the Company's controlled release formulation of physostigmine being tested for the treatment of Alzheimer's Disease. Monurol is a single dose antibiotic being tested for use in the treatment of uncomplicated urinary tract infections. The Company anticipates a continued increase in research and development expense as these and other potential products are developed and tested.
		 FOREST LABORATORIES, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (CONTINUED)
The Company has not elected to adopt SFAS No. 115 "Accounting for Certain Investments in Debt and Equity Securities" early. However, if adopted, the change would not have had a material effect on the Company's financial statements.
Inflation has not had a material effect on the Company's operations for the periods presented.
		FOREST LABORATORIES, INC. AND SUBSIDIARIES 		------------------------------------------ 		 CONSOLIDATED FINANCIAL STATEMENTS 	 --------------------------------- 		 YEARS ENDED MARCH 31, 1994, 1993 AND 1992 		 -----------------------------------------
REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS - - --------------------------------------------------
Board of Directors and Shareholders Forest Laboratories, Inc. New York, New York
We have audited the accompanying consolidated balance sheets of Forest Laboratories, Inc. and Subsidiaries as of March 31, 1994 and 1993, and the related consolidated statements of income, shareholders' equity and cash flows for each of the three years in the period ended March 31, 1994. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Forest Laboratories, Inc. and Subsidiaries as of March 31, 1994 and 1993, and the results of their operations and their cash flows for each of the three years in the period ended March 31, 1994 in conformity with generally accepted accounting principles.
/s/ BDO SEIDMAN ----------------------- 					 BDO SEIDMAN
New York, New York May 2, 1994
PAGE
		 FOREST LABORATORIES, INC. AND SUBSIDIARIES
			 CONSOLIDATED BALANCE SHEETS 				 (IN THOUSANDS)
							 MARCH 31, 					 ------------------------ 							 1994 1993 						 --------- --------- ASSETS - - ------ Current assets: Cash (including cash equivalent investments of $181,094 $172,286 $176,336 in 1994 and $160,180 in 1993) Accounts receivable, less allowances of $4,918 in 1994 and $4,630 in 1993 111,670 90,965 Inventories 37,180 38,221 Deferred income taxes 12,172 9,039 Other current assets 5,424 4,125 						 -------- -------- Total current assets 347,540 314,636 						 -------- -------- Long-term marketable securities 47,953 20,058 						 -------- -------- Property, plant and equipment: Land and buildings 43,264 20,324 Machinery and equipment 21,483 19,131 Vehicles and other 8,968 9,676 						 -------- -------- 						 73,715 49,131
Less accumulated depreciation 20,694 19,320 						 -------- -------- 						 53,021 29,811 						 -------- -------- Other assets: Excess of cost of investment in subsidiaries over net assets acquired, less accumulated amortization of $5,614 in 1994 and $4,988 in 1993 19,345 19,971 License agreements and other intangible assets, net 131,824 123,677 Deferred income taxes 3,787 6,520 Other 15,741 5,839 						 -------- -------- 						 170,697 156,007 						 -------- -------- 						 $619,211 $520,512 						 ======== ======== 							
		 FOREST LABORATORIES, INC. AND SUBSIDIARIES
			 CONSOLIDATED BALANCE SHEETS 		 (IN THOUSANDS, EXCEPT FOR PAR VALUES)
					 		 MARCH 31, 						 ----------------------- 						 1994 1993 						 -------- -------- LIABILITIES AND SHAREHOLDERS' EQUITY - - ------------------------------------ Current liabilities: Accounts payable $ 10,507 $ 7,958 Accrued expenses 25,552 21,191 Income taxes payable 16,164 11,996 						 -------- -------- Total current liabilities 52,223 41,145 						 -------- -------- Deferred income taxes 206 191 					 -------- -------- Commitments and contingencies
Shareholders' equity: Series A junior participating preferred stock, $1.00 par; shares authorized 1,000 in 1994 and 200 in 1993; no shares issued or outstanding Common stock $.10 par; shares authorized 250,000 in 1994 and 100,000 in 1993; issued 46,276 shares in 1994 and 45,515 shares in 1993 4,628 4,551 Capital in excess of par 266,233 253,257 Retained earnings 337,611 257,413 Cumulative foreign currency translation adjustments ( 3,817) ( 2,658) 						 -------- -------- 						 604,655 512,563 Less common stock in treasury, at cost (2,587 shares in 1994 and 2,490 shares in 1993) 37,873 33,387 						 -------- -------- 						 566,782 479,176 						 -------- -------- 						 $619,211 $520,512 						 ======== ========
SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS. 								
PAGE
		 CONSOLIDATED STATEMENTS OF INCOME 	 (IN THOUSANDS, EXCEPT PER SHARE DATA)
						 YEAR ENDED MARCH 31, 					 ----------------------------- 					 	 1994 1993 1992 					 -------- -------- --------
Net sales $351,641 $285,364 $239,193 Other income 9,680 11,070 9,244 					 -------- -------- -------- 					 361,321 296,434 248,437 					 -------- -------- -------- Costs and expenses: Cost of sales 64,150 53,629 48,219 Selling, general and administrative 143,695 118,108 101,236 Research and development 27,998 22,054 17,771 Interest 1,957 3,706 					 -------- -------- -------- 					 235,843 195,748 170,932 					 -------- -------- -------- Income before income taxes 125,478 100,686 77,505
Income taxes 45,280 36,379 27,936 					 -------- -------- -------- Net income $ 80,198 $ 64,307 $ 49,569 			 		 ======== ======== ======== Earnings per common and common equivalent share:
Primary $1.75 $1.42 $1.13 					 	===== ===== ===== Fully diluted $1.72 $1.41 $1.13 						===== ===== ===== Weighted average number of common and common equivalent shares outstanding:
Primary 45,957 45,432 43,992 					 ====== ====== ====== Fully diluted 46,614 45,764 44,044 					 ====== ====== ======
SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS.
PAGE
	 	 FOREST LABORATORIES, INC. AND SUBSIDIARIES
		CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY 		 YEARS ENDED MARCH 31, 1994, 1993 AND 1992
SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS.
		 FOREST LABORATORIES, INC. AND SUBSIDIARIES
		 CONSOLIDATED STATEMENTS OF CASH FLOWS 				 (IN THOUSANDS) 									 		 				 YEAR ENDED MARCH 31, 					 -------------------------------- 					 	1994 1993 1992 					 -------- -------- -------- Cash flows from operating activities: Net income $ 80,198 $ 64,307 $ 49,569 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation 3,763 3,868 3,581 Amortization 6,915 6,646 6,730 Deferred income tax benefit ( 385) ( 13,797) ( 2,491) Foreign currency transaction 	 (gain) loss ( 240) 108 ( 189) Net change in operating assets 	 and liabilities: 	 Decrease (increase) in: 	 Accounts receivable, net ( 20,705) ( 18,224) ( 18,803) 	 Inventories 1,041 ( 7,457) ( 10,558) 	 Other current assets ( 1,299) ( 872) 119 	 Increase (decrease) in: 	 Accounts payable 2,549 ( 864) 2,624 	 Accrued expenses 4,361 3,087 6,321 	 Income taxes payable 4,168 6,048 3,834 	 Decrease (increase) in other 	 assets ( 9,902) ( 5,280) 40 					 -------- -------- ------ 	 Net cash provided by operating 	 activities 70,464 37,570 40,777 					 -------- -------- ------ Cash flows from investing activities: Purchase of property, plant and equipment, net ( 27,070) ( 6,255) ( 3,642) Purchase of license agreements and other intangibles ( 14,436) ( 12,612) ( 962) Redemption (purchase) of long-term marketable securities ( 27,895) 894 					 -------- -------- -------- 	 Net cash used in investing 	 activities ( 69,401) ( 17,973) ( 4,604) 					 -------- -------- --------
		 FOREST LABORATORIES, INC. AND SUBSIDIARIES
		 CONSOLIDATED STATEMENTS OF CASH FLOWS 				 (IN THOUSANDS)
	 					 YEAR ENDED MARCH 31, 						 ---------------------------- 					 	1994 1993 1992 					 -------- ------- --------
Cash flows from financing activities: Net proceeds from common stock options exercised by employees under stock option plans and warrants 6,682 8,907 3,528 Tax benefit realized from the exercise of stock options by employees 1,885 36,180 2,443 Proceeds from sale of stock 53,386 Repayment of debt ( 23,069) ( 21,931) 					 -------- -------- -------- 	 Net cash provided by 	 financing activities 8,567 22,018 37,426 					 -------- -------- -------- Effect of exchange rate changes on cash ( 822) ( 2,806) 342 					 -------- -------- -------- Increase in cash and cash equivalents 8,808 38,809 73,941 Cash and cash equivalents, beginning of year 172,286 133,477 59,536 					 -------- -------- -------- Cash and cash equivalents, end of year $181,094 $172,286 $133,477 					 ======== ======== ========
Supplemental disclosures of cash flow information:
(In thousands) 1994 1993 1992 					 -------- -------- -------- Cash paid during the year for: Interest $ 4,999 $ 2,055 Income taxes $ 39,612 7,967 24,150 					 -------- -------- --------
SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS.
PAGE
	 	 FOREST LABORATORIES, INC. AND SUBSIDIARIES
		 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:
BASIS OF CONSOLIDATION: The consolidated financial statements include the accounts of Forest Laboratories, Inc. (the "Company") and its subsidiaries, all of which are wholly owned. All significant intercompany accounts and transactions have been eliminated.
INVENTORIES: Inventories are stated at the lower of cost or market, with cost determined on the first-in, first-out basis.
LONG-TERM MARKETABLE SECURITIES: Long-term marketable securities are stated at amortized cost, which approximates market, and consist of investments in municipal bonds maturing through 1996 and bonds of the Commonwealth of Puerto Rico maturing through 2002. Statement of Financial Accounting Standards No. 115, "Accounting for Certain Investments in Debt and Equity Securities", shall be effective for the Company's fiscal year beginning April 1, 1994. The Company has not elected to adopt this statement early, however if adopted, the change would not have had a material effect on the Company's financial position and results of operations as of and for March 31, 1994.
PROPERTY, PLANT AND EQUIPMENT AND DEPRECIATION: Property, plant and equipment are stated at cost. Depreciation is provided over the estimated useful lives of the assets primarily by the straight-line method.
INTANGIBLE ASSETS: The excess of cost of investment over the fair value of net assets of subsidiaries at the time of acquisition is being amortized over 35 to 40 years. The costs of obtaining license agreements and other intangible assets are being amortized over the estimated lives of the assets, 10 to 40 years.
CASH EQUIVALENTS: Cash equivalents consist of short-term, highly liquid investments (primarily municipal bonds with interest rates that are re-set weekly) which are readily convertible into cash at par value (cost).
REVENUE RECOGNITION: Sales are recorded in the period the merchandise is shipped.
RESEARCH AND DEVELOPMENT: Expenditures for research and development are charged to expense as incurred.
SAVINGS AND PROFIT SHARING PLANS: The Company's domestic and Puerto Rican subsidiaries have savings and profit sharing plans. Under these plans, substantially all non-bargaining unit employees may participate in the plans after becoming eligible (as defined). The profit sharing plan contributions are primarily at the discretion of the Company. The savings plan contributions include a matching contribution made by Company. Savings and profit sharing contributions amounted to $2,818,000, $1,959,000 and $1,601,000 for 1994, 1993 and 1992, respectively.
		 FOREST LABORATORIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: (CONTINUED)
EARNINGS PER SHARE: Earnings per share are based on the weighted average number of common and common equivalent shares outstanding during each year. Common equivalent shares consist of the dilutive effect of unissued shares under options and warrants, computed using the treasury stock method (using the average stock prices for primary basis and the higher of average or period end stock prices for fully diluted basis). At March 31, 1994, 1993 and 1992, the primary and fully diluted common equivalent shares amounted to 2,672,000 and 3,329,000, 3,346,000 and 3,678,000 and 4,992,000 and 5,044,000, respectively.
INCOME TAXES: The Company adopted Statement of Financial Accounting Standards No. 109, "Accounting for Income Taxes", for the year ended March 31, 1993 and, accordingly, has accounted for income taxes on the liability method. Under the liability method, deferred income taxes are provided on the differences in bases of assets and liabilities between financial reporting and tax returns using enacted tax rates. Previously, the Company utilized the deferred method when accounting for income taxes. The effect of this accounting change had an immaterial impact on the consolidated results ofoperations for the year ended March 31, 1993 and no cumulative effect adjustment was required as of April 1, 1992.
2. BUSINESS OPERATIONS:
The Company and its subsidiaries, which are located in the United States, Puerto Rico, the United Kingdom and Ireland, manufacture and market ethical and other pharmaceutical products. Information about the Company's sales and profitability by different geographic areas for the years ended March 31, 1994, 1993 and 1992 follows:
PAGE
		 FOREST LABORATORIES, INC. AND SUBSIDIARIES
	 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
2.	 BUSINESS OPERATIONS: (CONTINUED)
The Company sells primarily in the United States and European markets. Operating profit is net sales less operating expenses, and does not include other income, unallocated expenses or income taxes. PAGE
	 	 FOREST LABORATORIES, INC. AND SUBSIDIARIES
	 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
3. INVENTORIES:
Inventories consist of the following:
MARCH 31, (IN THOUSANDS) 1994 1993 						 ------- ------- Raw materials $13,250 $11,490 Work in process 3,012 2,664 Finished goods 20,918 24,067 							 ------- ------- 							 $37,180 $38,221 							 ======= ======= 4. OTHER ASSETS:
License agreements and other intangible assets consist of the following:
MARCH 31, (IN THOUSANDS, EXCEPT FOR ESTIMATED WHICH ARE STATED IN YEARS) Estimated - - ----------------------------------------- lives 1994 1993 					 --------- -------- -------- License agreements 10-40 $ 67,799 $ 53,361 Trade names 20-40 34,190 34,190 Goodwill 25-40 29,412 29,412 Non-compete agreements 10-13 22,987 22,987 Customer lists 10 3,506 3,506 Other 10-40 3,568 3,570 						-------- -------- 							 161,462 147,026 Less accumulated amortization ( 29,638) ( 23,349) 						-------- -------- 							$131,824 $123,677 							======== ======== 5. ACCRUED EXPENSES:
Accrued expenses consist of the following:
MARCH 31, (IN THOUSANDS) 1994 1993 					 ------- -------
Employee compensation and other benefits $ 6,975 $ 6,620 Clinical research 3,451 3,800 Customer discounts 4,045 2,500 Royalties 3,064 2,800 Other 8,017 5,471 							 ------- ------- 							 $25,552 $21,191 							 ======= =======
		 FOREST LABORATORIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
6. COMMITMENTS:
LEASES: The Company leases manufacturing, office and warehouse facilities, equipment and automobiles under operating leases expiring through 1999. Rent expense approximated $4,215,000 for 1994, $3,213,000 for 1993 and $3,142,000 for 1992. Aggregate minimum rentals under noncancellable leases are as follows:
YEAR ENDING MARCH 31, (IN THOUSANDS) 1995 $3,152 1996 1,883 1997 1,002 1998 413 1999 350 								 ------ 								 $6,800 							 ======
									 ROYALTY OBLIGATIONS: In connection with the product rights acquisition of Armour-R- Thyroid, Levothroid-R- and Thyrolar-R- on December 31, 1990, the Company was required to pay royalties of 10% of the related product sales in excess of defined amounts. In December 1992, the Company prepaid such royalties for $7,000,000. Royalty expense under this agreement totalled $778,000, $778,000 and $570,250 in 1994, 1993 and 1992, respectively. At March 31, 1994, $5,250,000 remains prepaid and is appropriately included and other assets and is being amortized over seven years.
In July 1992, the Company acquired the worldwide rights to the product Flumadine-R- for $20 million. The Company paid $10 million upon the execution of the agreement, and the remaining $10 million was paid at the time of the product launch in October 1993. The Company was also required to pay royalties of 10% of product sales in excess of defined amounts. In January 1994, the Company prepaid such royalties for $10 million. Royalty expense under this agreement for 1994 amounted to $417,000. At March 31, 1994, $9,583,000 remains prepaid and is appropriately included in current and other assets is being amortized over eleven years.
In 1984 and 1986, the Company entered into agreements for research and development (the "1984 Prutech Agreement" and "1986 Prutech Agreement") with Prutech Research and Development Partnership ("Prutech"). In accordance with the provisions of these agreements, the Company granted Prutech nonexclusive licenses to certain of the Company's controlled release technologies for the purpose of developing certain products. Prutech contracted with the Company to perform research necessary to develop the products. In addition, Prutech granted the Company options (some of which were exercised) to acquire exclusive manufacturing and marketing rights to the products if they are successfully developed. Under the 1984 Prutech Agreement, the Company is paying to Prutech royalties of 12% on sales of the products. The Company paid to Prutech royalty payments of $7,732,000, $6,273,000 and $5,200,000 in 1994, 1993 and 1992, respectively. Under the 1986 Prutech Agreement, the Company will pay to Prutech an initial royalty on sales of the products of 7%, decreasing to 2%, through December 31, 1999. No royalties have been incurred under this agreement.
		 FOREST LABORATORIES, INC. AND SUBSIDIARIES 					 	 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
7. SHAREHOLDERS' EQUITY:
PREFERRED STOCK PURCHASE RIGHTS: On February 18, 1988, the Company's Board of Directors declared a distribution of one preferred stock purchase right for each outstanding share of common stock. Each right will entitle the holder to buy one one-hundredth of a share of authorized Series A Junior Participating Preferred Stock ("Series A Preferred Stock") at an exercise price of $60 per right, subject to adjustment. Prior to becoming exercisable, the rights are evidenced by the certificates representing the common stock may not be traded apart from the common stock. The rights become exercisable on the tenth day after public announcements that a person or group has acquired, the right to acquire, 20% or more of the Company's outstanding common stock, or an announcement of a tender offer that would result in a beneficial ownership by a person or group of 20% or more of the Company's common stock.
If, after the rights become exercisable, the Company is a party to certain merger or business combination transactions, or transfers 50% or more of its assets or earning power, or if an acquirer engages in certain self-dealing transactions, each right (except for those held by the acquirer) will entitle its holder to buy a number of shares of the Company's Series A Preferred Stock or, in certain circumstances, a number of shares of the acquiring company's common stock, in either case having a value equal to two-and-one-half times the exercise price of the right. The rights may be redeemed by the Company at any time up to ten days after a person or group acquires 20% or more of the Company's common stock at a redemption price of $.001 per right. The rights will expire on February 17, 1998.
STOCK OPTIONS: The Company has various Employee Stock Option Plans whereby options to purchase an aggregate of 9,800,000 shares of common stock have been or remain to be issued to employees of the Company and its subsidiaries at prices not less than the fair market value of the common stock at the date of grant. 						
PAGE
FOREST LABORATORIES, INC. AND SUBSIDIARIES 	 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
7. SHAREHOLDERS EQUITY: (CONTINUED)
Transactions under the stock option plans and individual non-qualified options not under the plans are summarized as follows: 									 Non- 						 Stock qualified 						 option individual 						 plans options 						 --------- ---------- Shares under option at April 1, 1991 (at $4.02 to $24.25 per share) 5,050,112 3,171,498 Granted (at $35.31 to $39.69 per share) 302,650 8,000 Exercised (at $4.02 to $24.25 per share) ( 315,510) (1,501,000) Cancelled ( 92,090) 						 --------- --------- Shares under option at March 31, 1992 (at $6.59 to $39.69 per share) 4,945,162 1,678,498 Granted (at $32.25 to $42.81 per share) 741,100 8,000 Exercised (at $6.59 to $24.25 per share) (1,719,884) ( 21,800) Cancelled ( 45,890) 						 --------- ---------
Shares under option at March 31, 1993 (at $6.59 to $42.81 per share) 3,920,488 1,664,698
Granted (at $30.00 to $44.50 per share) 422,650 6,000 Exercised (at $9.91 to $42.81 per share) ( 349,165) ( 11,600) Cancelled ( 67,055) 					 --------- --------- Shares under option at March 31, 1994 (at $6.59 to $44.50 per share) 3,926,918 1,659,098 						 ========= ========= Options exercisable at March 31: 1992 3,751,442 1,585,698 1993 2,452,168 1,612,498 1994 2,511,247 1,607,498
At March 31, 1994 and 1993, 348,373 and 709,968 shares, respectively, were available for grant.
			 FOREST LABORATORIES, INC.
	 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
8. CONTINGENCIES:
The Company is subject to several product liability and other claims which Management does not believe will have a material effect on the Company.
The Company and certain of its officers are defendants in a putative class action alleging certain misrepresentations in disclosures related to Micturin. The Company is a nominal defendant in a putative derivative action against the Company's directors arising from such disclosures and challenging the validity of certain options granted to the director defendants. Management believes the claims are without merit and intends to vigorously defend the actions.
The Company has been served in several civil actions in various federal district courts and in the Superior Court of California in San Francisco. In each case, the actions were filed against many major pharmaceutical manufacturers and suppliers, including the Company, alleging price discrimination in the sale of pharmaceutical products in violation of federal law (and, in the case of the California actions, California law) and related anti-trust claims. The actions were brought by pharmacies (in certain cases purporting to represent a class) and seek injunctive relief and monetary damages. The manufacturer defendants, including the Company, have filed motions to dismiss and demurrers in each of the actions. On February 4, 1994, the Judicial Panel on District Litigation has ordered the federal actions consolidated for coordinated proceedings in the Federal District Court for the Northern District of Illinois (Chicago). The Company believes the lawsuits are without merit and intends to defend them vigorously.
9. OTHER INCOME:
Other income consists of the following:
YEAR ENDED MARCH 31, (IN THOUSANDS) 1994 1993 1992 - - ------------------------------------ ------ ------- ------ Interest and dividends $7,077 $ 7,521 $5,489 Research revenue 51 1,228 Commissions 1,342 3,245 1,874 Other 1,261 253 653 					 ------ ------- ------ 					 $9,680 $11,070 $9,244 					 ====== ======= ====== 10. INCOME TAXES:
The Company and its mainland U.S. subsidiaries file a consolidated federal income tax return.
Income before income taxes includes income from foreign operations of $7,615,000, $8,163,000 and $6,025,000 for the years ended March 31, 1994, 1993 and 1992, respectively.
The Company has tax holidays in Puerto Rico and Ireland which expire primarily in 1997 and 2010, respectively. The net impact of these tax holidays was to increase net income and net income per share (primary) by approximately $1,938,000 and $.04 in 1994, $2,571,000 and $.06 in 1993 and $2,924,000 and $.07 in 1992.
	 	 FOREST LABORATORIES, INC. AND SUBSIDIARIES
	 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
10. INCOME TAXES: (CONTINUED)
The provision for income taxes consists of the following:
YEAR ENDED MARCH 31, (IN THOUSANDS) 1994 1993 1992 - - ----------------------------------- ------- ------- ------- Current: U.S. federal $36,845 $ 7,810 $23,020 State and local 4,909 3,575 3,364 Foreign 2,026 2,611 1,600 			 ------- ------- ------- 					 43,780 13,996 27,984 					 ------- ------- ------- Deferred: Domestic ( 382) ( 13,677) ( 2,697) Foreign ( 3) ( 120) 206 				 ------- ------- ------- 					 ( 385) ( 13,797) ( 2,491) 					 ------- ------- ------- Charge in lieu of income taxes, relating to the tax effect of stock option tax deduction 1,885 36,180 2,443 					 ------- ------- ------- 					 $45,280 $36,379 $27,936 					 ======= ======= ======= 								 No provision has been made for income taxes on the undistributed earnings of the Company's foreign subsidiaries of approximately $35,391,000 at March 31, 1994, as the Company intends to indefinitely reinvest such earnings.
The reasons for the difference between the provision for income taxes and expected federal income taxes at statutory rates are as follows:
YEAR ENDED MARCH 31, (IN THOUSANDS) 1994 1993 1992 - - ----------------------------------- ------- ------- ------- Expected federal income taxes $43,917 $34,233 $26,352 State and local income taxes, less federal income tax benefit 3,274 3,745 2,581 Benefit of tax-exempt earnings of subsidiaries ( 2,348) ( 2,838) ( 2,762) Benefit of tax-exempt earnings not available (utilized) in current year ( 234) 126 37 Tax effect of permanent differences 631 838 171 Other 40 275 1,557 				 ------- ------- ------- 					 $45,280 $36,379 $27,936 					 ======= ======= =======
		 FOREST LABORATORIES, INC. AND SUBSIDIARIES
	 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
10. INCOME TAXES (CONTINUED)
Net deferred income taxes as of March 31, 1994 and 1993 consist of the following (IN THOUSANDS): 							 1994 1993 						 ------- ------- Inventory valuation $ 992 $ 776 Receivable reserves and other allowances 6,848 3,616 State and local net operating loss carryforwards 3,724 6,814 Depreciation ( 1,523) ( 1,583) Amortization 3,353 1,106 Tax credits and other carryforwards 226 1,753 Accrued liabilities 1,162 624 Other 971 2,262 						 ------- ------- 						 $15,753 $15,368 					 ======= =======
Deferred income tax benefits for the year ended March 31, 1992 resulted from the recognition of revenue and expense items in different periods for financial reporting and tax purposes. Principally, items making up deferred income taxes include tax over book depreciation, provisions for uncollectible accounts receivable and provisions for inventory.
11. QUARTERLY FINANCIAL DATA (UNAUDITED): (IN THOUSANDS, EXCEPT PER SHARE DATA) 								 Primary 								 earnings 1994 Net sales Gross profit Net income per share - - ---- --------- ------------ ---------- --------- First quarter $79,251 $65,174 $17,544 $.39 Second quarter 82,814 67,375 19,547 .43 Third quarter 96,996 79,425 20,809 .45 Fourth quarter 92,580 75,517 22,298 .48
- - ---- First quarter $65,743 $52,464 $13,969 $.31 Second quarter 69,841 56,347 15,797 .35 Third quarter 75,472 61,701 16,739 .37 Fourth quarter 74,308 61,223 17,802 .39
Fully diluted earnings per share are not presented, as the results obtained are substantially the same as primary earnings per share.
PAGE
				 EXHIBIT 24(a)
CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
Forest Laboratories, Inc. New York, New York
We hereby consent to the incorporation by reference in the Registration Statement of Forest Laboratories, Inc. on Form S-8, filed with the Securities and Exchange Commission on November 13, 1990, of our reports dated May 2, 1994, on the consolidated financial statements and schedules of Forest Laboratories, Inc. and Subsidiaries, included or incorporated by reference in the Forest Laboratories, Inc. Annual Report on Form 10-K for the year ended March 31, 1994.
				 /s/ BDO Seidman 				 ------------------------- 				BDO Seidman
New York, New York June 27, 1994